Turning Point Brands (TPB) 10-Q 27 Apr 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	Apr. 19, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Document Transition Report	false
Entity File Number	001-37763
Entity Registrant Name	TURNING POINT BRANDS, INC.
Entity Central Index Key	0001290677
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-0709285
Entity Address, Address Line One	5201 Interchange Way
Entity Address, City or Town	Louisville
Entity Address, State or Province	KY
Entity Address, Postal Zip Code	40229
City Area Code	502
Local Phone Number	778-4421
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	TPB
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,136,353

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash	$ 126,045	$ 128,320
Accounts receivable, net of allowances of $177 in 2022 and $262 in 2021	9,450	6,496
Inventories	105,858	87,607
Other current assets	25,663	26,746
Total current assets	267,016	249,169
Property, plant, and equipment, net	20,567	18,650
Deferred income taxes	1,754	1,363
Right of use assets	14,405	15,053
Deferred financing costs, net	362	388
Goodwill	162,323	162,333
Other intangible assets, net	87,022	87,485
Master Settlement Agreement (MSA) escrow deposits	30,237	31,720
Other assets	35,017	35,399
Total assets	618,703	601,560
Current liabilities:
Accounts payable	29,464	7,361
Accrued liabilities	29,921	32,937
Other current liabilities	38	38
Total current liabilities	59,423	40,336
Notes payable and long-term debt	414,791	414,172
Lease liabilities	12,625	13,336
Total liabilities	486,839	467,844
Commitments and contingencies
Stockholders' equity:
Preferred stock; $0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-	0	0
Additional paid-in capital	109,073	108,811
Cost of repurchased common stock (1,605,632 shares at March 31, 2022, and 1,295,408 shares at December 31, 2021)	(59,491)	(48,869)
Accumulated other comprehensive loss	(1,326)	(195)
Accumulated earnings	81,327	71,460
Non-controlling interest	2,083	2,312
Total stockholders' equity	131,864	133,716
Total liabilities and stockholders' equity	618,703	601,560
Common Stock, Voting [Member]
Stockholders' equity:
Common stock	198	197
Common Stock, Nonvoting [Member]
Stockholders' equity:
Common stock	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Accounts receivable, allowance	$ 177	$ 262
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	40,000,000	40,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Repurchased common stock (in shares)	1,605,632	1,295,408
Common Stock, Voting [Member]
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	190,000,000	190,000,000
Common stock, shares issued (in shares)	19,785,806	19,690,884
Common stock, shares outstanding (in shares)	18,180,174	18,395,476
Common Stock, Nonvoting [Member]
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, shares issued (in shares)	0	0
Common stock, shares outstanding (in shares)	0	0

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Consolidated Statements of Income [Abstract]
Net sales	$ 100,894	$ 107,641
Cost of sales	49,100	54,380
Gross profit	51,794	53,261
Selling, general, and administrative expenses	32,565	28,912
Operating income	19,229	24,349
Interest expense, net	5,196	4,486
Investment income	(78)	(25)
Loss on extinguishment of debt	0	5,706
Income before income taxes	14,111	14,182
Income tax expense	3,340	2,654
Consolidated net income	10,771	11,528
Net loss attributable to non-controlling interest	(227)	(255)
Net income attributable to Turning Point Brands, Inc.	$ 10,998	$ 11,783
Basic income per common share:
Net income attributable to Turning Point Brands, Inc. (in dollars per share)	$ 0.60	$ 0.62
Diluted income per common share:
Net income attributable to Turning Point Brands, Inc. (in dollars per share)	$ 0.55	$ 0.57
Weighted average common shares outstanding:
Basic (in shares)	18,257,695	19,093,961
Diluted (in shares)	21,749,510	22,665,067

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Consolidated Statements of Comprehensive Income [Abstract]
Consolidated net income	$ 10,771	$ 11,528
Other comprehensive income (loss), net of tax
Unrealized loss on MSA investments, net of tax	(1,126)	(452)
Foreign currency translation, net of tax	(7)	318
Unrealized gain on derivative instruments, net of tax	0	2,448
Other comprehensive income, net of tax	(1,133)	2,314
Consolidated comprehensive income	9,638	13,842
Comprehensive loss attributable to non-controlling interest	(229)	(96)
Comprehensive income attributable to Turning Point Brands, Inc.	$ 9,867	$ 13,938

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Other comprehensive income (loss), net of tax
Unrealized loss on MSA investments, tax	$ 357	$ 144
Foreign currency translation, tax	0	0
Unrealized gain on derivative instruments, tax	$ 0	$ 937

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Consolidated net income	$ 10,771	$ 11,528
Adjustments to reconcile net income to net cash provided by operating activities:
Loss on extinguishment of debt	0	5,706
Loss (gain) on sale of property, plant, and equipment	1	(2)
Depreciation expense	871	788
Amortization of other intangible assets	463	477
Amortization of deferred financing costs	645	604
Deferred income tax (benefit) expense	(34)	552
Stock compensation expense	1,159	1,498
Noncash lease (income) expense	(5)	6
Gain on investments	(14)	(13)
Changes in operating assets and liabilities:
Accounts receivable	(2,958)	2,735
Inventories	(18,258)	(12,461)
Other current assets	1,081	1,283
Other assets	382	464
Accounts payable	22,101	14,882
Accrued liabilities and other	(3,165)	(3,806)
Net cash provided by operating activities	13,040	24,241
Cash flows from investing activities:
Capital expenditures	(2,787)	(842)
Restricted cash, MSA escrow deposits	(8,468)	(14,920)
Proceeds on the sale of property, plant and equipment	1	2
Net cash used in investing activities	(11,254)	(15,760)
Cash flows from financing activities:
Proceeds from Senior Secured Notes	0	250,000
Payments of 2018 first lien term loan	0	(130,000)
Settlement of interest rate swaps	0	(3,573)
Payment of dividends	(1,022)	(958)
Payments of financing costs	0	(6,614)
Exercise of options	245	425
Redemption of options	0	(1,466)
Redemption of performance restricted stock units	(1,141)	0
Common stock repurchased	(10,622)	(5,733)
Net cash provided by (used in) financing activities	(12,540)	102,081
Net (decrease) increase in cash	(10,754)	110,562
Effect of foreign currency translation on cash	(3)	101
Cash, beginning of period:
Unrestricted	128,320	41,765
Restricted	15,155	35,074
Total cash at beginning of period	143,475	76,839
Cash, end of period:
Unrestricted	126,045	167,361
Restricted	6,673	20,141
Total cash at end of period	132,718	187,502
Supplemental schedule of noncash investing activities:
Accrued capital expenditures	187	177
Supplemental schedule of noncash financing activities:
Dividends declared not paid	1,131	1,071
Accrued expenses for incurred financing costs	$ 0	$ 301

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]Voting [Member]	Additional Paid-In Capital [Member]	Cost of Repurchased Common Stock [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Earnings [Member]	Non-Controlling Interest [Member]	Total
Beginning balance at Dec. 31, 2020	$ 195	$ 102,423	$ (10,191)	$ (2,635)	$ 23,645	$ 4,050	$ 117,487
Beginning balance (in shares) at Dec. 31, 2020							19,133,794
Unrealized loss on MSA investments, net of tax	0	0	0	(452)	0	0	$ (452)
Unrealized gain on derivative instruments, net of tax	0	0	0	2,448	0	0	2,448
Foreign currency translation, net of tax	0	0	0	159	0	159	318
Stock compensation expense	0	1,498	0	0	0	0	1,498
Exercise of options	$ 1	424	0	0	0	0	425
Exercise of options (in shares)	44,357
Redemption of options	$ 0	(1,466)	0	0	0	0	(1,466)
Cost of repurchased common stock	0	0	$ (5,733)	0	0	0	(5,733)
Cost of repurchased common stock (in shares)			(119,031)
Dividends	0	0	$ 0	0	(1,071)	0	(1,071)
Net income	0	0	0	0	11,783	(255)	11,528
Ending balance at Mar. 31, 2021	196	102,879	(15,924)	(480)	34,357	3,954	$ 124,982
Ending balance (in shares) at Mar. 31, 2021							19,059,120
Beginning balance at Dec. 31, 2020	195	102,423	(10,191)	(2,635)	23,645	4,050	$ 117,487
Beginning balance (in shares) at Dec. 31, 2020							19,133,794
Ending balance at Dec. 31, 2021	197	108,811	(48,869)	(195)	71,460	2,312	$ 133,716
Ending balance (in shares) at Dec. 31, 2021							18,395,476
Unrealized loss on MSA investments, net of tax	0	0	0	(1,126)	0	0	$ (1,126)
Unrealized gain on derivative instruments, net of tax							0
Foreign currency translation, net of tax	0	0	0	(5)	0	(2)	(7)
Stock compensation expense	0	1,159	0	0	0	0	1,159
Exercise of options	$ 0	245	0	0	0	0	245
Exercise of options (in shares)	25,166
Performance restricted stock units issuance	$ 1	(1)	0	0	0	0	0
Performance restricted stock units issuance (in shares)	103,843
Performance restricted stock units redeemed	$ 0	(1,141)	0	0	0	0	(1,141)
Performance restricted stock units redeemed (in shares)	(34,087)
Cost of repurchased common stock	$ 0	0	$ (10,622)	0	0	0	$ (10,622)
Cost of repurchased common stock (in shares)			(310,224)				(310,224)
Dividends	0	0	$ 0	0	(1,131)	0	$ (1,131)
Net income	0	0	0	0	10,998	(227)	10,771
Ending balance at Mar. 31, 2022	$ 198	$ 109,073	$ (59,491)	$ (1,326)	$ 81,327	$ 2,083	$ 131,864
Ending balance (in shares) at Mar. 31, 2022							18,180,174

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Consolidated Statements of Changes in Stockholders' Equity [Abstract]
Unrealized loss on MSA investments, tax	$ 357	$ 144
Unrealized gain on derivative instruments, tax	0	937
Foreign currency translation, tax	$ 0	$ 0

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Description of Business and Basis of Presentation [Abstract]
Description of Business and Basis of Presentation	Note 1. Description of Business and Basis of Presentation Description of Business T consisting of staple products with its iconic brands Zig-Zag ® and Stoker’s ® focus segments are led by its core, proprietary brands: Zig-Zag ® in the Zig-Zag Products segment; Stoker’s ® along with Beech-Nut ® and Trophy ® in the Stoker’s Products segment; along with its distribution platforms ( Vapor Beast ® , VaporFi ® and Direct Vapor ® ) and Solace ® in the NewGen Products segment. retail outlets in North America. The Company operates in three segments: (i) Zig-Zag Products, (ii) Stoker’s Products, and (iii) NewGen Products. Basis of Presentation T he accompanying unaudited interim, consolidated financial statements have been prepared in accordance with the accounting practices described in the Company’s audited, consolidated financial statements as of and for the year ended December 31, 2021. In the opinion of management, the unaudited, interim, consolidated financial statements included herein contain all adjustments necessary to present fairly the financial position, results of operations, and cash flows of the Company for the periods indicated. Such adjustments, other than nonrecurring adjustments separately disclosed, are of a normal and recurring nature. The operating results for interim periods are not necessarily indicative of results to be expected for a full year or future interim periods. The unaudited, interim, consolidated financial statements should be read in conjunction with the Company’s audited, consolidated financial statements and accompanying notes as of and for the year ended December 31, 2021. The accompanying interim, consolidated financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and, accordingly, do not include all the disclosures required by generally accepted accounting principles in the United States (“GAAP”) with respect to annual financial statem

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Consolidation The consolidated financial statements include the accounts of the Company, its subsidiaries, all of which are wholly-owned, and variable interest entities (“VIEs”) for which the Company is considered the primary beneficiary. All significant intercompany transactions have been eliminated . Revenue Recognition The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606), which includes excise taxes and shipping and handling charges billed to customers, net of cash discounts for prompt payment, sales returns and incentives, upon delivery of goods to the customer – at which time the Company’s performance obligation is satisfied - at an amount that the Company expects to be entitled to in exchange for those goods in accordance with the five-step analysis outlined in Topic 606: (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) performance obligations are satisfied. The Company excludes from the transaction price, sales taxes and value-added taxes imposed at the time of sale (which do not include excise taxes on smokeless tobacco, cigars or vaping products billed to customers). The Company records an allowance for sales returns, based principally on historical volume and return rates, which is included in accrued liabilities on the consolidated balance sheets. The Company records sales incentives, which consist of consumer incentives and trade promotion activities, as a reduction in revenues (a portion of which is based on amounts estimated as being due to wholesalers, retailers and consumers at the end of the period) based principally on historical volume and utilization rates. Expected payments for sales incentives are included in accrued liabilities on the consolidated balance sheets. A further requirement of ASC 606 is for entities to disaggregate revenue recognized from contracts with customers into categories that depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The Company’s management views business performance through segments that closely resemble the performance of major product lines. Thus, the primary and most useful disaggregation of the Company’s contract revenue for decision making purposes is the disaggregation by segment which can be found in Note 17. An additional disaggregation of contract revenue by sales channel can be found within Note 17 as well. Shipping Costs The Company records shipping costs incurred as a component of selling, general, and administrative expenses. Shipping costs incurred were approximately $5.7 million and $5.9 million for the three months ending March 31, 2022 and 2021, respectively. Inventories Inventories are stated at the lower of cost or net realizable value using the first-in, first-out (“FIFO”) method. Leaf tobacco is presented in current assets in accordance with standard industry practice, notwithstanding the fact that such tobaccos are carried longer than one year for the purpose of curing. Fair Value GAAP establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy under GAAP are described below: ● Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets at the measurement date. ● Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. ● Level 3 – Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Derivative Instruments Foreign Currency Forward Contracts: The Company enters into foreign currency forward contracts to hedge a portion of its exposure to changes in foreign currency exchange rates on inventory purchase commitments. The Company accounts for its forward contracts under the provisions of ASC 815, Derivatives and Hedging. Under the Company’s policy, the Company may hedge up to 100% of its anticipated purchases of inventory in the denominated invoice currency over a forward period not to exceed twelve months. The Company may also, from time to time, hedge up to ninety percent of its non-inventory purchases in the denominated invoice currency. Forward contracts that qualify as hedges are adjusted to their fair value through other comprehensive income as determined by market prices on the measurement date, except any hedge ineffectiveness which is recognized currently in income. Gains and losses on these forward contracts are transferred from other comprehensive income into inventory as the related inventories are received and are transferred to net income as inventory is sold. Changes in fair value of any contracts that do not qualify for hedge accounting or are not designated as hedges are recognized currently in income. Interest Rate Swap Agreements: The Company enters into interest rate swap contracts to manage interest rate risk and reduce the volatility of future cash flows. The Company accounts for its interest rate swap contracts under the provisions of ASC 815, Derivatives and Hedging. Swap contracts that qualify as hedges are adjusted to their fair value through other comprehensive income as determined by market prices on the measurement date, except any hedge ineffectiveness which is recognized currently in income. Gains and losses on these swap contracts are transferred from other comprehensive income into net income upon settlement of the derivative position or at maturity of the interest rate swap contract. Changes in fair value of any contracts that do not qualify for hedge accounting or are not designated as hedges are recognized currently in income. Risks and Uncertainties Manufacturers and sellers of tobacco products are subject to regulation at the federal, state, and local levels. Such regulations include, among others, labeling requirements, limitations on advertising, and prohibition of sales to minors. The tobacco industry is likely to continue to be heavily regulated. There can be no assurance as to the ultimate content, timing, or effect of any regulation of tobacco products by any federal, state, or local legislative or regulatory body, nor can there be any assurance that any such legislation or regulation would not have a material adverse effect on the Company’s financial position, results of operations, or cash flows. In a number of states, targeted flavor bans have been proposed or enacted legislatively or by the administrative process. Depending on the number and location of such bans, that legislation or regulation could have a material adverse effect on the Company’s financial position, results of operations or cash flows. Food and Drug Administration (“FDA”) continues to consider various restrictive regulations around our products, including targeted flavor bans; however, the details, timing, and ultimate implementation of such measures remain unclear. The tobacco industry has experienced, and is experiencing, significant product liability litigation. Most tobacco liability lawsuits have been brought against manufacturers and sellers of cigarettes for injuries allegedly caused by smoking or exposure to smoke. However, several lawsuits have been brought against manufacturers and sellers of smokeless products for injuries to health allegedly caused by use of smokeless products. Typically, such claims assert that use of smokeless products is addictive and causes oral cancer. Additionally, several lawsuits have been brought against manufacturers and distributors of NewGen products due to malfunctioning devices. There can be no assurance the Company will not sustain losses in connection with such lawsuits and that such losses will not have a material adverse effect on the Company’s financial position, results of operations, or cash flows. Master Settlement Agreement (MSA): Pursuant to the Master Settlement Agreement (the “MSA”) entered into in November 1998 by most states (represented by their attorneys general acting through the National Association of Attorneys General) and subsequent states’ statutes, a “cigarette manufacturer” (which is defined to include a manufacturer of make-your-own (“MYO”) cigarette tobacco) has the option of either becoming a signatory to the MSA or opening, funding, and maintaining an escrow account to have funds available for certain potential tobacco-related liabilities with sub-accounts on behalf of each settling state. Such companies are entitled to direct the investment of the escrowed funds and withdraw any appreciation but cannot withdraw the principal for twenty-five years from the year of each annual deposit, except to withdraw funds deposited pursuant to an individual state’s escrow statute to pay a final judgement to that state’s plaintiffs in the event of such a final judgement against the Company. The Company chose to open and fund an escrow account as its method of compliance. It is the Company’s policy to record amounts on deposit in the escrow account for prior years as a non-current asset. The Company has chosen to invest a portion of the MSA escrow, from time to time, in U.S. Government securities including TIPS, Treasury Notes, and Treasury Bonds. These investments are classified as available-for-sale and carried at fair value. Realized losses are prohibited under the MSA; any investment in an unrealized loss position will be held until the value is recovered, or until maturity. Fair values for the U.S. Governmental agency obligations are Level 2 in the fair value hierarchy. The following tables show cost and estimated fair value of the assets held in the MSA account, respectively, as well as the maturities of the U.S. Governmental agency obligations held in such account for the periods indicated. As of March 31, 2022 As of December 31, 2021 Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Cash and cash equivalents $ 3,673 $ - $ - $ 3,673 $ 12,155 $ - $ - $ 12,155 U.S. Governmental agency obligations (unrealized position < 12 months) 21,452 5 (1,145 ) 20,312 19,918 4 (357 ) 19,565 U.S. Governmental agency obligations (unrealized position > 12 months) 6,948 - (696 ) 6,252 - - - - $ 32,073 $ 5 $ (1,841 ) $ 30,237 $ 32,073 $ 4 $ (357 ) $ 31,720 As of March 31, Less than one year $ - One to five years 7,443 Five to ten years 20,001 Greater than ten years 956 Total $ 28,400 The following shows the amount of deposits by sales year for the MSA escrow account: Deposits as of Sales Year March 31, 2022 December 31, 2021 1999 $ 211 $ 211 2000 1,017 1,017 2001 1,673 1,673 2002 2,271 2,271 2003 4,249 4,249 2004 3,714 3,714 2005 4,553 4,553 2006 3,847 3,847 2007 4,167 4,167 2008 3,364 3,364 2009 1,619 1,619 2010 406 406 2011 193 193 2012 199 199 2013 173 173 2014 143 143 2015 101 101 2016 91 91 2017 82 82 Total $ 32,073 $ 32,073 Food and Drug Administration (FDA): On June 22, 2009, the Family Smoking Prevention and Tobacco Control Act (the “ FSPTCA On August 8, 2016, the FDA deeming regulation became effective. The deeming regulation gave the FDA the authority to also regulate cigars, pipe tobacco, e-cigarettes, vaporizers, and e-liquids as “deemed” tobacco products under the FSPTCA. The FDA assesses tobacco product user fees on six c lasses of regulated tobacco products and computes user fees using a methodology similar to the methodology used by the U.S Department of Agriculture to compute the Tobacco Transition Payment Program (“TTPP,” also known as the “Tobacco Buyout”) assessment. First, the total, annual, congressionally established user fee assessment is allocated among the various classes of tobacco products using the federal excise tax weighted market share of tobacco products subject to regulation. Then, the assessment for each class of tobacco products is divided among individual manufacturers and importers In August 2016, the FDA’s regulatory authority under the Tobacco Control Act (the “TCA”) Under the deeming regulations, the FDA has responsibility for conducting premarket review of “new tobacco products”—defined as those products not commercially marketed in the United States as of February 15, 2007. There are three pathways for obtaining premarket authorization, including submission of a premarket tobacco product application (“PMTA”). We submitted premarket filings prior to the September 9, 2020 deadline for certain of our products and have continued to supplement these applications with additional information. A successful PMTA must demonstrate that the subject product is “appropriate for the protection of public health,” taking into account the effect of the marketing of the product on all sub-populations while a Substantial Equivalence Report must demonstrate that a new product either has the same characteristics as its predicate product or different characteristics, but does not raise different questions of public health. The FDA has indicated its enforcement priority is those applicants who have received negative action on their application, such as a Marketing Denial Order or Refuse to File notification and who continue to illegally sell those unauthorized products, as well as products for which manufacturers failed to submit a marketing application. The FDA has issued a number of proposed rules related to premarket filings; however, those rules were not finalized prior to the September 9, 2020, deadline. On October 5, 2021, the FDA finalized two rules related to the Substantial Equivalence process and the Premarket Tobacco Product Application process, respectively, which both become effective November 4, 2021. Both final rules (collectively, the “Rules”) indicate that any new or additional requirements will not retroactively apply to currently pending PMTAs; however, the information outlined in the rule remains important to the FDA’s substantive review of an application. We believe we have products that meet the Rules and have filed premarket filings supporting a showing of the respective required standards. However, there is no assurance that the FDA’s guidance or regulations will not change, that the FDA will not prioritize its enforcement in a manner that negatively affects our pending applications, or that unforeseen circumstances will not arise that prevent us from sufficiently supplementing or completing our applications or otherwise increase the amount of time and money we are required to spend to receive all necessary marketing orders. Although we filed many premarket applications in a timely manner, no assurance can be given that the applications will ultimately be successful. This may result in the prioritization of supplementing or completing applications for high priority SKUs in our inventory position, which could adversely impact future revenues generated by lower priority SKUs. In addition, we currently distribute many third-party manufactured vapor products for which we will be completely dependent on the manufacturer complying with the premarket filing requirements. There can be no assurance that these third-party products will receive a marketing order or otherwise remain in compliance with relevant legal requirements. While we will take measures to pursue regulatory compliance for our own privately-branded or proprietary vape products that compete with these third-party products, there is no assurance that such proprietary products would be as successful in the marketplace or can fully displace third-party products that are currently being distributed by us, which could adversely affect our results of operations and liquidity. For a period of time after the filing deadline, we expect there to be a lack of enforcement, which may adversely affect our ability to compete in the marketplace against those who continue to sell unauthorized products. On April 29, 2021, the FDA announced plans to propose two tobacco product standards related to combusted tobacco products: (1) a ban on menthol as a characterizing flavor in cigarettes; and (2) a ban on all characterizing flavors (including menthol) in cigars. These product standards are required to go through the formal rulemaking process where we would have the opportunity to comment on the proposed rule with regard to any impact on any of our products. The FDA’s policy on these and other regulated products may change or expand over time in ways not yet known and may significantly impact our products or our premarket filings. On March 15, 2022, the Consolidated Appropriations Act of 2022 was signed into law. This law included a new provision bringing non-tobacco nicotine products (“NTN Products”), including synthetic nicotine, under the jurisdiction of the FDA Center for Tobacco Products. This law took effect April 14, 2022, and subjects NTN Products to the same requirements as tobacco-derived products, including not selling these products to persons under 21 years of age, not marketing these products as modified risk tobacco products, and not distributing free samples of these products. Additionally, NTN Products on the market between March 15, 2022, and April 14, 2022, must file a PMTA by May 14, 2022. NTN Products subject of a timely-filed PMTA, and not in receipt of a negative action, may remain on the market until July 13, 2022. After July 13, 2022, these products are subject to enforcement. We have been compiling premarket filings for certain of our NTN Products and will submit these filings ahead of the May 14, 2022, deadline. After the deadline passes, we will continue to supplement these filings with additional information; however, there can be no guarantee that FDA will accept such amendments or, similar to other filings, that the applications will meet the standard of “appropriate for the protection of public health.” We also expect that for a period of time after the filing deadline, there may be a lack of enforcement, which may adversely impact our ability to compete in the marketplace against those who continue to sell unauthorized products. Prevent All Cigarette Trafficking Act (“PACT Act”): On December 27, 2020, President Trump signed the Further Consolidated Appropriations Act, 2021, into law. This law included an amendment to the Jenkins Act expanding the definition of “cigarette” to include “electronic nicotine delivery systems,” or ENDS, and required that the United States Postal Service (USPS) promulgate regulations clarifying the applicability of the prohibition on delivery sales of cigarettes to ENDS. USPS issued its final rule on October 21, 2021. We have received appropriate shipping exemptions from carrier services we use to carry the affected freight. Failure to comply with the PACT Act could result in significant financial or criminal penalties. To the extent we are unable to respond to, or comply with, these new requirements, we could lose our shipping exemptions, be subject to civil or criminal penalties, or there could be a material adverse effect on our business, results of operations and financial condition.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2022
Acquisitions [Abstract]
Acquisitions	Note 3. Acquisitions Unitabac In July 2021, the Company acquired certain assets of Unitabac, a marketer of mass-market cigars, for $10.7 million in total consideration, comprised of $9.6 million in cash and $1.1 million of capitalized transaction costs. The acquisition is comprised of a portfolio of cigarillo products and all related intellectual property, including Cigarillo Non-Tip (“NT”) Homogenized Tobacco Leaf (“HTL”) products and Rolled Leaf and Natural Leaf Cigarillo Products. The transaction was accounted for as an asset purchase with $10.0 million assigned to intellectual property, which has an indefinite life, and $0.7 million assigned to inventory. The intellectual property asset is deductible for tax purposes. Direct Value Wholesale In April 2021, Turning Point Brands Canada, a VIE for which the Company is considered the primary beneficiary, purchased 100% of the equity interests of Westhem Ventures LTD d/b/a Direct Value Wholesale (“DVW”) for $3.9 million, net of cash acquired, with $3.5 million paid in cash at closing and $0.5 million in accrued consideration to be paid during 2021. DVW is a Canadian distribution entity that operates in markets not primarily served by Turning Point Brands Canada. The acquisition expands Turning Point Brands Canada’s markets in Canada. On April 13, 2021, in connection with the acquisition of DVW, the Company provided a $3.7 million unsecured loan to Turning Point Brands Canada bearing interest at 8% per annum and maturing April 13, 2023. The unsecured loan is eliminated in the consolidation of Turning Point Brands Canada. As of March 31, 2022, Turning Point Brands Canada had not completed the accounting for the acquisition. The following table summarizes the consideration transferred and calculation of goodwill based on excess of the acquisition price over the estimated fair value of the identifiable net assets acquired and are based on management’s preliminary estimates: Total consideration transferred $ 3,462 Adjustments to consideration transferred: Cash acquired (43 ) Accrued consideration 472 Adjusted consideration transferred 3,891 Assets acquired: Working capital (primarily AR and inventory) 1,334 Fixed assets and Other long term assets 27 Net assets acquired $ 1,361 Goodwill $ 2,530 The goodwill of $2.5 million consists of the synergies expected from combining the operations and is deductible for tax purposes. Turning Point Brands Canada In July 2021, the Company invested an additional $2.3 million in Turning Point Brands Canada increasing its ownership interest to 65%. The Company received board seats aligned with its ownership position. The Company has determined that Turning Point Brands Canada continues to be a VIE due to its required subordinated financial support. The Company has determined it remains the primary beneficiary due to its 65% equity interest, additional subordinated financing and distribution agreement with Turning Point Brands Canada for the sale of the Company’s products. As a result of the Company remaining the primary beneficiary, the increase in ownership interest resulted in a decrease in Non-controlling interest of $1.1 million and a decrease in Additional paid-in capital of $1.1 million

Derivative Instruments

Derivative Instruments	3 Months Ended
	Mar. 31, 2022
Derivative Instruments [Abstract]
Derivative Instruments	Note 4. Derivative Instruments Foreign Currency The Company’s policy is to manage the risks associated with foreign exchange rate movements. The policy allows hedging of up to 100% of its anticipated purchases of inventory over a forward period that will not exceed rolling and consecutive months. The Company may, from time to time, hedge currency for non-inventory purchases, e.g. , production equipment, not to exceed of the purchase price. At March 31, 2022 and December 31, 2021, the Company had no forward contracts outstanding. Interest Rate Swaps The Company’s policy is to manage interest rate risk relating to the volatility of future cash flows associated with debt instruments bearing interest at variable rates. In March 2018, the Company executed various interest rate swap agreements for a notional amount of $70 million with an expiration of December 2022. The swap agreements fixed LIBOR at 2.755%. The swap agreements met the hedge accounting requirements; thus, any change in fair value was recorded to other comprehensive income. The Company used the Shortcut Method to account for the swap agreements. The Shortcut Method assumes the hedge to be perfectly effective; thus, there is ineffectiveness to be recorded in earnings. The Company terminated the interest rate swap agreement in conjunction with the prepayment of all outstanding amounts under the Lien Credit Facility (as defined below) in the quarter of in the amount of $ million which was reclassified out of accumulated other comprehensive loss into loss on extinguishment of debt.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2022
Fair Value of Financial Instruments [Abstract]
Fair Value of Financial Instruments	Note 5. Fair Value of Financial Instruments The estimated fair value amounts have been determined by the Company using the methods and assumptions described below. However, considerable judgment is required to interpret market data to develop estimates of fair value. Accordingly, the estimates presented herein are not necessarily indicative of the amounts the Company could realize in a current market exchange. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. Cash and Cash Equivalents Cash and cash equivalents are, by definition, short-term. Thus, the carrying amount is a reasonable estimate of fair value. Accounts Receivable The fair value of accounts receivable approximates their carrying value due to their short-term nature. Long-Term Debt The Company’s Senior Secured Notes (as defined below) bear interest at a rate of 5.625% per year. As of March 31, 2022, the fair value of the Senior Secured Notes approximated their carrying value of $250 million due to the recency of the notes’ issuance, related to March 31, 2022. As of December 31, 2021, the fair value of the Senior Secured Notes approximated their carrying value of $250 million due to the recency of the notes’ issuance, related to December 31, 2021. The Convertible Senior Notes (as defined) bear interest at a rate of 2.50% per year, and the fair value of the Convertible Senior Notes without the conversion feature approximated , with a carrying value of as of March 31, 2022 As of December 31, 2021 the fair value of the Convertible Senior Notes approximated , with a carrying value of . See Note 11, “Notes Payable and Long-Term Debt”, for further information regarding the Company’s long-term debt.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2022
Inventories [Abstract]
Inventories	Note 6. Inventories The components of inventories are as follows: March 31, 2022 December 31, 2021 Raw materials and work in process $ 7,483 $ 6,936 Leaf tobacco 47,733 35,900 Finished goods - Zig-Zag Products 28,928 25,663 Finished goods - Stoker’s Products 11,142 8,959 Finished goods - NewGen products 9,167 8,591 Other 1,405 1,558 Inventories $ 105,858 $ 87,607 The inventory valuation allowance was $5.4 million and $7.7 million as of March 31, 2022, and December 31, 2021, respectively.

Other Current Assets

Other Current Assets	3 Months Ended
	Mar. 31, 2022
Other Current Assets [Abstract]
Other Current Assets	Note 7. Other Current Assets Other current assets consist of: March 31, 2022 December 31, 2021 Inventory deposits $ 9,245 $ 12,091 Insurance deposit 3,000 3,000 Other 13,418 11,655 Total $ 25,663 $ 26,746

Property, Plant, and Equipment

Property, Plant, and Equipment	3 Months Ended
	Mar. 31, 2022
Property, Plant, and Equipment [Abstract]
Property, Plant, and Equipment	Note 8. Property, Plant, and Equipment Property, plant, and equipment consists of: March 31, 2022 December 31, 2021 Land $ 22 $ 22 Buildings and improvements 3,096 3,096 Leasehold improvements 5,389 5,374 Machinery and equipment 22,322 19,591 Furniture and fixtures 9,380 9,402 Gross property, plant and equipment 40,209 37,485 Accumulated depreciation (19,642 ) (18,835 ) Net property, plant and equipment $ 20,567 $ 18,650

Other Assets

Other Assets	3 Months Ended
	Mar. 31, 2022
Other Assets [Abstract]
Other Assets	Note 9. Other Assets Other assets consist of: March 31, 2022 December 31, 2021 Equity investments $ 25,617 $ 25,649 Debt security investment 8,000 8,000 Other 1,400 1,750 Total $ 35,017 $ 35,399 The Company records its equity investments without a readily determinable fair value, that are not accounted for under the equity method, at cost, with adjustments for impairment and observable price changes. In July, 2021, the Company invested $8 million in Old Pal Holding Company LLC (“Old Pal”). The Company invested in the form of a convertible note which includes additional follow-on investment rights. Old Pal is a leading brand in the cannabis lifestyle space that operates a non-plant touching licensing model. The Company’s investment will enable Old Pal to expand product offerings in existing states, which include California, Nevada, Michigan, Oklahoma, Ohio, Washington and Massachusetts, and will help create the infrastructure necessary to support continued territory and product expansion. The convertible note bears an interest rate of 3.0% per year and matures July 31, 2026. Interest and principal are payable at maturity. Old Pal has the option to extend the maturity date in one-year increments. The interest rate is subject to change based on sales levels of Old Pal meeting certain thresholds. The weighted average interest rate was 3% for the three months ended March 31, 2022. Old Pal has the option to convert the note into shares once sales reach a certain threshold. Additionally, the Company has the right to convert the note into shares at any time after January 1, 2022. The conditions required to allow Old Pal to convert the note were not met as of March 31, 2022. The Company has classified the debt security with Old Pal as available for sale. The fair value of the debt security approximated its carrying value of $8.0 million at March 31, 2022 , due to the recency of the debt security’s purchase, related to each such date. The Company has recorded accrued interest receivable of $0.2 million at March 31, 2022 , in other current assets on our Consolidated Balance Sheets. In April 2021, the Company invested $8.7 million in Docklight Brands, Inc., a pioneering consumer products company with celebrated brands including Marley Natural Marley Marley

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2022
Accrued Liabilities [Abstract]
Accrued Liabilities	Note 10. Accrued Liabilities Accrued liabilities consist of: March 31, 2022 December 31, 2021 Accrued payroll and related items $ 4,768 $ 6,974 Customer returns and allowances 6,257 6,497 Taxes payable 5,269 2,053 Lease liabilities 3,034 2,976 Accrued interest 2,724 7,318 Other 7,869 7,119 Total $ 29,921 $ 32,937

Notes Payable and Long-Term Deb

Notes Payable and Long-Term Debt	3 Months Ended
	Mar. 31, 2022
Notes Payable and Long-Term Debt [Abstract]
Notes Payable and Long-Term Debt	Note 11. Notes Payable and Long-Term Debt Notes payable and long-term debt consists of the following in order of preference: March 31, 2022 December 31, 2021 Senior Secured Notes $ 250,000 $ 250,000 Convertible Senior Notes 172,500 172,500 Gross notes payable and long-term debt 422,500 422,500 Less deferred finance charges (7,709 ) (8,328 ) Notes payable and long-term debt $ 414,791 $ 414,172 Senior Secured Notes On February 11, 2021, the Company closed a private offering (the “Offering”) of $250 million aggregate principal amount of its 5.625% senior secured notes due 2026 (the “Senior Secured Notes”). The Senior Secured Notes bear interest at a rate of 5.625% and will mature on February 15, 2026. Interest on the Senior Secured Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing on August 15, 2021.The Company used the proceeds from the Offering (i) to repay all obligations under and terminate the 2018 First Lien Credit Facility, (ii) to pay related fees, costs, and expenses and (iii) for general corporate purposes. Obligations under the Senior Secured Notes are guaranteed by the Company’s existing and future wholly-owned domestic subsidiaries (the “Guarantors”) that guarantee any Credit Facility (as defined in the Indenture governing the Senior Secured Notes or the “Senior Secured Notes Indenture”) or capital markets debt securities of the Company or Guarantors in excess of $ 15.0 million. The and the related guarantees are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions. The Company may redeem the Senior Secured Notes, in whole or in part, at any time prior to February 15, 2023, at a price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid interest, if any, to, but excluding the applicable redemption date, plus a “make-whole” premium. Thereafter, the Company may redeem the Senior Secured Notes, in whole or in part, at established redemption prices set forth in the Senior Secured Notes Indenture, plus accrued and unpaid interest, if any. In addition, on or prior to February 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the Senior Secured Notes with the net cash proceeds from certain equity offerings at a redemption price equal to 105.625%, plus accrued and unpaid interest, if any to the redemption date; provided, however , If the Company experiences a change of control (as defined in the Senior Secured Notes Indenture), the Company must offer to repurchase the Senior Secured Notes at a repurchase price equal to 101% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest. The Indenture contains covenants that, among other things, restrict the ability of the Company and its restricted subsidiaries to: (i) grant or incur liens; (ii) incur, assume or guarantee additional indebtedness; (iii) sell or otherwise dispose of assets, including capital stock of subsidiaries; (iv) make certain investments; (v) pay dividends, make distributions or redeem or repurchase capital stock; (vi) engage in certain transactions with affiliates; and (vii) consolidate or merge with or into, or sell substantially all of our assets to another entity. These covenants are subject to a number of limitations and exceptions set forth in the Indenture. The Indenture provides for customary events of default . The Company was in compliance with all covenants as of March 31, 2022. The Company incurred debt issuance costs attributable to the issuance of the Senior Secured Notes of $6.4 million which are amortized to interest expense using the effective interest method over the expected life of the Senior Secured Notes. 2021 Revolving Credit Facility In connection with the Offering, the Company also entered into a new $25 million senior secured revolving credit facility (the “ 2021 Revolving Credit Facility”) with the lenders party thereto (the “Lenders”) and Barclays Bank PLC, as administrative agent and collateral agent (in such capacity, the “Agent”). The 2021 Revolving Credit Facility provides for a revolving line of credit of up to $ million. Letters of credit are limited to $ million (and are a part of, and not in addition to, the revolving line of credit). The Company has t drawn any borrowings under the 2021 Revolving Credit Facility but does have letters of credit of approximately $ million outstanding under the facility. The 2021 Revolving Credit Facility will mature on , if none of the Company’s Convertible Senior Notes are outstanding, and if any Convertible Senior Notes are outstanding, the date which is days prior to the maturity date of July 15, 2024, for such Convertible Senior Notes. Interest is payable on the 2021 Revolving Credit Facility at a fluctuating rate of interest determined by reference to the Eurodollar rate plus an applicable margin of 3.50% (with step-downs upon de-leveraging). The Company also has the option to borrow at a rate determined by reference to the base rate. The obligations under the 2021 Revolving Credit Agreement are guaranteed on a joint and several basis by the Guarantors. The Company’s and Guarantors’ obligations under the 2021 Revolving Credit Facility are secured on a pari passu basis with the Senior Secured Notes. The 2021 Revolving Credit Agreement contains covenants that are substantially the same as the covenants in the Senior Secured Notes Indenture. The 2021 Revolving Credit Facility also requires the maintenance of a Consolidated Leverage Ratio (as defined in the 2021 Revolving Credit Agreement) of 5.50 to 1.00 (with a step down to 5.25 to 1.00 beginning with the fiscal quarter ending March 31, 2023) at the end of each fiscal quarter when extensions of credit under the 2021 Revolving Credit Facility and certain drawn and undrawn letters of credit (excluding (a) letters of credit that have been cash collateralized and (b) letters of credit having an aggregate face amount less than $5,000,000) in the aggregate outstanding exceeds 35% of the total commitments under the 2021 Revolving Credit Facility. The 2021 Revolving Credit Agreement provides for customary events of default. The Company was in compliance with all covenants as of March 31, 2022. The Company incurred debt issuance costs attributable to the issuance of the 2021 Revolving Credit Facility of $ 0.5 million which are amortized to interest expense using the effective interest method over the expected life of the 2021 Revolving Credit Facility. 2018 First Lien Credit Facility The 2018 First Lien Term Loan and the 2018 Revolving Credit Facility bore interest at LIBOR plus a spread of 2.75% to 3.50% based on the Company’s senior leverage ratio. The Company used a portion of the proceeds from the issuance of the Senior Secured Notes to prepay all outstanding amounts under and terminate the 2018 First Lien Credit Facility in the first quarter of 2021 in the amount of $130.0 million, and the transaction resulted in a $5.7 million loss on extinguishment of debt. Convertible Senior Notes In July 2019, the Company closed an offering of $172.5 million in aggregate principal amount of its 2.50% Convertible Senior Notes due July 15, 2024 (the “Convertible Senior Notes”). The Convertible Senior Notes bear interest at a rate of 2.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The Convertible Senior Notes will mature on July 15, 2024, unless earlier repurchased, redeemed or converted. The Convertible Senior Notes are senior unsecured obligations of the Company. The Convertible Senior Notes are convertible into approximately 3,209,690 shares of TPB Common Stock under certain circumstances prior to maturity at a conversion rate of 18.607 shares per $1,000 principal amount of the Convertible Senior Notes, which represents a conversion price of approximately $53.74 per share, subject to adjustment under certain conditions, but will not be adjusted for any accrued and unpaid interest. The conversion price is adjusted periodically as a result of dividends paid by the Company in excess of pre-determined thresholds of $0.04 per share. Upon conversion, the Company may pay cash, shares of common stock or a combination of cash and stock, as determined by the Company at its discretion. The conditions required to allow the holders to convert their Convertible Senior Notes were not met as of March 31, 2022. The Company incurred debt issuance costs attributable to the Convertible Senior Notes of $5.9 million which are amortized to interest expense using the effective interest method over the expected life of the Convertible Senior Notes. In connection with the Convertible Senior Notes offering, the Company entered into privately negotiated capped call transactions with certain financial institutions. The capped call transactions have a strike price of $53.74 per and a cap price of $82.86 per share, and are exercisable when, and if, the Convertible Senior Notes are converted. The Company paid $20.53 million for these capped calls at the time they were entered into and charged that amount to additional paid-in capital. Promissory Note On June 10, 2020 , in connection with the acquisition of certain Durfort assets, the Company issued the Promissory Note in the principal amount of $ million, with an annual interest rate of , payable , with the interest payment due . The Company prepaid all outstanding amounts under and terminated the Promissory Note in the third quarter of 2021 in the amount of $9.6 million. The transaction resulted in a $0.4 million gain on extinguishment of debt. Unsecured Loan On April 6, 2020 , the Lien Credit Facility was amended to allow for an unsecured loan under the Coronavirus Aid, Relief, and Economic Security Act of (“CARES”). On , National Tobacco Company, L.P., a subsidiary of the Company, entered into a loan agreement with Regions Bank guaranteed by the Small Business Administration for a $ million unsecured loan. The proceeds of the loan were received on . The loan was scheduled to mature on and had a interest rate . During 2021, the Company applied for forgiveness for the loan. On October 15, 2021, the Company received notice that its application for forgiveness was fully approved. The extinguishment of the unsecured loan occurred in the fourth quarter of 2021, resulting in a $7.5 million gain on extinguishment of debt . The Company is subject to audit relating to the unsecured loan until 2027 which could result in repayment of some or all of the unsecured loan previously forgiven. However, the Company believes that repayment of any amount is not probable.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	Note 12. Leases The Company’s leases consist primarily of leased property for manufacturing, warehouse, head offices and retail space as well as vehicle leases. At lease inception, the Company recognizes a lease right of use asset and lease liability calculated as the present value of future minimum lease payments. In general, the Company does not recognize any renewal periods within the lease terms as there are no significant barriers to ending the lease at the initial term. Lease and non-lease components are accounted for as a single lease component. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for these leases is recognized on a straight-line basis over the lease term. The components of lease expense consisted of the following: Three Months Ended March 31, 2022 2021 Operating lease cost Cost of sales $ 227 $ 225 Selling, general and administrative 690 752 Variable lease cost (1) 112 205 Short-term lease cost 14 11 Sublease income - (30 ) Total $ 1,043 $ 1,163 (1) Variable lease cost includes elements of a contract that do not represent a good or service but for which the lessee is responsible for paying. March 31, 2022 December 31, 2021 Assets: Right of use assets $ 14,405 $ 15,053 Total lease assets $ 14,405 $ 15,053 Liabilities: Current lease liabilities $ 3,034 $ 2,976 Long-term lease liabilities 12,625 13,336 Total lease liabilities $ 15,659 $ 16,312 (2) Reported within accrued liabilities on the balance sheet As of March 31, 2022 2021 Weighted-average remaining lease term - operating leases 6.5 years 7.1 years Weighted-average discount rate - operating leases 4.88 % 4.93 % Nearly all the lease contracts for the Company do not provide a readily determinable implicit interest rate. For these contracts, the Company uses a discount rate that approximates its incremental borrowing rate at the time of the lease commencement. As of March 31, 2022, maturities of lease liabilities consisted of the following: March 31, 2022 2022 $ 2,775 2023 3,635 2024 2,460 2025 2,145 2026 2,085 Years thereafter 5,343 Total lease payments $ 18,443 Less: Imputed interest 2,784 Present value of lease liabilities $ 15,659

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Taxes [Abstract]
Income Taxes	Note 13. Income Taxes The Company’s effective income tax rate for the three months ended March 31, 2022 , was 23.7% which includes a discrete tax deduction of $0.4 million for the three months ended March 31, 2022 relating to stock option exercises. The Company’s effective income tax rate for the three months ended March 31, 2021 , was 18.7% which includes a discrete tax deduction of $3.3 million for the three months ended March 31, 2021 relating to stock option exercises . The Company follows the provisions of ASC 740-10-25, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company has determined that the Company did not have any uncertain tax positions requiring recognition under the provisions of ASC 740-10-25. The Company’s policy is to recognize interest and penalties accrued on uncertain tax positions, if any, as part of interest expense. The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. In general, the Company is no longer subject to U.S. federal and state tax examinations for years prior to 2018.

Share Incentive Plans

Share Incentive Plans	3 Months Ended
	Mar. 31, 2022
Share Incentive Plans [Abstract]
Share Incentive Plans	Note 14. Share Incentive Plans On March 22, 2021, the Company’s Board of Directors adopted the Turning Point Brands, Inc. 2021 Equity Incentive Plan (the “2021 Plan”), pursuant to which awards may be granted to employees, non-employee directors, and consultants. In addition, the 2021 Plan provides for the granting of nonqualified stock options to employees of the Company or any subsidiary of the Company. Pursuant to the 2021 Plan, 1,290,000 shares, plus 100,052 shares remaining available for issuance under the 2015 Equity Incentive Plan (the “2015 Plan”), of TPB Common Stock are reserved for issuance as awards to employees, non-employee directors, and consultants as compensation for past or future services or the attainment of certain performance goals. The 2021 Plan is scheduled to terminate on March 21, 2031. The 2021 Plan is administered by the compensation committee (the “Committee”) of the Company’s Board of Directors. The Committee determines the vesting criteria for the awards, with such criteria to be specified in the award agreement. As of March 31, 2022, net of forfeitures, there were Restricted Stock Units (“RSUs”), options and Performance-Based Restricted Stock Units (“PRSUs”) On April 28, 2016, the Board of Directors of the Company adopted the 2015 Plan, pursuant to which awards could have been granted to employees, non-employee directors, and consultants. In addition, the 2015 Plan provided for the granting of nonqualified stock options to employees of the Company or any subsidiary of the Company. Pursuant to the 2015 Plan, 1,400,000 shares of TPB Common Stock were reserved for issuance as awards to employees, non-employee directors, and consultants as compensation for past or future services or the attainment of certain performance goals. The 2015 Plan was scheduled to terminate on April 27, 2026. Upon adoption of the 2021 Plan, the 2015 Plan was terminated, and the Company determined additional grants would be made under the 2015 Plan. However, all awards issued under the 2015 Plan that have not been previously terminated or forfeited remain outstanding and continue unaffected. There are shares available for grant under the 2015 Plan. On February 8, 2006, the Board of Directors of the Company adopted the 2006 Equity Incentive Plan (the “2006 Plan”) of North Atlantic Holding Company, Inc., pursuant to which awards may be granted to employees. The 2006 Plan provides for the granting of nonqualified stock options and restricted stock awards to employees. Upon the adoption of the Company’s 2015 Equity Incentive Plan in connection with its IPO, the Company determined no additional grants would be made under the 2006 Plan. However, all awards issued under the 2006 Plan that have not been previously terminated or forfeited remain outstanding and continue unaffected. There are no shares available for grant under the 2006 Plan. Stock option activity for the 2006, 2015 and 2021 Plans is summarized below: Stock Option Shares Weighted Average Exercise Price Weighted Average Grant Date Fair Value Outstanding, December 31, 2020 711,060 $ 19.58 $ 6.42 Granted 119,500 50.93 13.58 Exercised (202,768 ) 10.22 6.35 Forfeited (7,957 ) 33.22 9.63 Outstanding, December 31, 2021 619,835 28.51 8.70 Granted 100,000 30.46 10.23 Exercised (25,166 ) 16.14 4.89 Forfeited (7,217 ) 29.53 8.13 Outstanding, March 31 2022 687,452 $ 29.23 $ 9.07 Under the 2006, 2015 and 2021 Plans, the total intrinsic value of options exercised during the three months ended March 31, 2022 and 2021, was $0.4 million, and $3.3 million, respectively. At March 31, 2022, under the 2006 Plan, the exercise price for the 86,377 outstanding options is $3.83 per share, all of which are exercisable. The weighted average of the remaining lives of the outstanding stock options with an exercise price of $3.83 is approximately 2.19 years. The Company estimates the expected life of these stock options is ten years from the date of grant. For the $3.83 per share options, the weighted average fair value of options at the date of grant was determined using the Black-Scholes model with the following assumptions a ten-year life from grant date, a current share price and exercise price of $3.83, a risk-free interest rate of 3.57%, volatility of 40%, and no assumed dividend yield. Based on these assumptions, the fair value of these options is approximately $2.17 per share option granted. At March 31, 2022, under the 2015 and 2021 Plans, the risk-free interest rate is based on the U.S. Treasury rate for the expected life at the time of grant. The expected volatility is based on the average long-term historical volatilities of peer companies. We intend to continue to consistently use the same group of publicly traded peer companies to determine expected volatility until sufficient information regarding volatility of our share price becomes available or until the selected companies are no longer suitable for this purpose. Due to our limited trading history, we are using the simplified method presented by SEC Staff Accounting Bulletin No. 107 to calculate expected holding periods, which represent the periods of time for which options granted are expected to be outstanding. We will continue to use this method until we have sufficient historical exercise experience to give us confidence in the reliability of our calculations. The fair values of these options were determined using the Black-Scholes option pricing model. The following table outlines the assumptions based on the number of options granted under the 2015 Plan. February 10, 2017 May 17, 2017 March 7, 2018 March 20, 2019 October 24, 2019 March 18, 2020 February 18, 2021 May 3, 2021 Number of options granted 40,000 93,819 98,100 155,780 25,000 155,000 100,000 12,000 Options outstanding at March 31 2022 20,000 46,483 58,667 142,284 25,000 94,612 94,529 12,000 Number exercisable at March 31 2022 20,000 46,483 58,667 142,284 25,000 62,148 39,386 4,080 Exercise price $ 13.00 $ 15.41 $ 21.21 $ 47.58 $ 20.89 $ 14.85 $ 51.75 $ 47.76 Remaining lives 4.87 5.13 5.94 6.98 7.57 7.97 8.89 9.10 Risk free interest rate 1.89 % 1.76 % 2.65 % 2.34 % 1.58 % 0.79 % 0.56 % 0.84 % Expected volatility 27.44 % 26.92 % 28.76 % 30.95 % 31.93 % 35.72 % 28.69 % 29.03 % Expected life 6.000 6.000 6.000 6.000 6.000 6.000 6.000 6.000 Dividend yield - - 0.83 % 0.42 % 0.95 % 1.49 % 0.55 % 0.59 % Fair value at grant date $ 3.98 $ 4.60 $ 6.37 $ 15.63 $ 6.27 $ 4.41 $ 13.77 $ 13.06 The following table outlines the assumptions based on the number of options granted under the 2021 Plan. May 17, 2021 March 14, 2022 Number of options granted 7,500 100,000 Options outstanding at March 31 2022 7,500 100,000 Number exercisable at March 31 2022 2,550 - Exercise price $ 45.05 $ 30.46 Remaining lives 9.13 9.96 Risk free interest rate 0.84 % 2.10 % Expected volatility 31.50 % 35.33 % Expected life 6.000 6.000 Dividend yield 0.63 % 1.01 % Fair value at grant date $ 13.23 $ 10.23 The Company has recorded compensation expense related to the options based on the provisions of ASC 718 under which the fixed portion of such expense is determined as the fair value of the options on the date of grant and amortized over the vesting period. The Company recorded compensation expense related to the options of approximately $0.2 million and $0.3 million for the three months ended March 31, 2022 and 2021, respectively. Total unrecognized compensation expense related to options at March 31, 2022, is $1.5 million, which will be expensed over 2.38 years. PRSUs are restricted stock units subject to both performance-based and service-based vesting conditions. The number of shares of TPB Common Stock a recipient will receive upon vesting of a PRSU will be calculated by reference to certain performance metrics related to the Company’s performance over a five-year period. PRSUs will vest on the measurement date, which is no more than days after the performance period provided the applicable service and performance conditions are satisfied. As of March 31, 2022 there are PRSUs outstanding, all of which are unvested. The following table outlines the PRSUs granted and outstanding as of March 31, 2022 March 7, 2018 March 20, 2019 July 19, 2019 March 18, 2020 December 28, 2020 February 18, 2021 March 14, 2022 Number of PRSUs granted 96,000 92,500 88,582 94,000 88,169 100,000 49,996 PRSUs outstanding at March 31 2022 89,600 77,380 21,342 86,610 58,779 93,840 49,996 Fair value as of grant date $ 21.21 $ 47.58 $ 52.15 $ 14.85 $ 46.42 $ 51.75 $ 30.46 Remaining lives 0.75 1.75 0.75 2.75 1.75 3.75 4.75 The Company recorded compensation expense related to the PRSUs of approximately $0.8 million and in the consolidated statements of income for the three months ended March 31, 2022 and 2021 respectively, based on the probability of achieving the performance condition. Total unrecognized compensation expense related to these awards at March 31, 2022 is which will be expensed over the service periods based on the probability of achieving the performance condition. The Company has granted 87,367 RSUs which vest over one May 4, 2021 July 23, 2021 March 14, 2022 March 14, 2022 Number of RSUs granted 7,478 1,159 50,004 28,726 RSUs outstanding at March 31, 2022 7,478 1,159 50,004 28,726 Fair value as of grant date $ 47.86 $ 51.81 $ 30.46 $ 30.46 Remaining lives 0.09 0.31 4.75 2.75 The Company has recorded compensation expense related to the RSUs based on the provisions of ASC 718 under which the fixed portion of such expense is determined as the fair value of the RSUs on the date of grant and amortized over the vesting period. The Company recorded compensation expense related to the RSUs of approximately $0.2 million for the three months ended March 31, 2022. Total unrecognized compensation expense related to RSUs at March 31, 2022, is $2.4 million, which will be expensed over 3.96 years.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2022
Contingencies [Abstract]
Contingencies	Note 15. Contingencies On October 9, 2020, a purported stockholder of Turning Point Brands, Inc., Paul-Emile Berteau, filed a complaint in the Delaware Court of Chancery relating to the merger of SDI with a TPB subsidiary pursuant to the Agreement and Plan of Merger and Reorganization, dated as of April 7, 2020, by and among TPB, SDI and Merger Sub. The complaint purports to assert derivative counts for breach of fiduciary duty on TPB’s behalf and against the TPB Board of Directors and certain SDI affiliates. The third count purports to assert a direct claim against TPB and its Board of Directors based on allegations that TPB’s Amended and Restated Bylaws are inconsistent with TPB’s certificate of incorporation. On October the TPB Board of Directors adopted Amendment No. to TPB’s Amended and Restated Bylaws, which amended the challenged section of the bylaws. On June the court granted in part and denied in part the defendants’ motions to dismiss. Among other things, the court dismissed TPB director H.C. Charles Diao as a defendant in the action and dismissed the count of the plaintiff’s complaint as moot. The remaining defendants answered the complaint on August While the Company believes it has good and valid defenses to the claims, there can be no assurance that the Company will prevail in this case, and it could have a material adverse effect on the Company’s business and results of operations. Other major tobacco companies are defendants in product liability claims. In a number of these cases, the amounts of punitive and compensatory damages sought are significant and, if such a claim were brought against the Company, could have a material adverse effect on our business and results of operations. The Company is subject to several lawsuits alleging personal injuries resulting from malfunctioning vaporizer devices or batteries and may be subject to claims in the future relating to other NewGen products. The Company is still evaluating these claims and the potential defenses to them. For example, the Company did not design or manufacture the products at issue; rather, the Company was merely the distributor. Nonetheless, there can be no assurance that the Company will prevail in these cases, and they could have a material adverse effect on the financial position, results of operations, or cash flows of the Company . We have several subsidiaries engaged in making, distributing, and selling vapor products. As a result of the overall publicity and controversy surrounding the vapor industry generally, many companies have received informational subpoenas from various regulatory bodies and in some jurisdictions regulatory lawsuits have been filed regarding marketing practices and possible underage sales. We expect that our subsidiaries will be subject to some such cases and investigative requests. In the acquisition of the vapor businesses, we negotiated financial “hold-backs”, which we expect to be able to use to defray expenses associated with the information production and the cost of defending any such lawsuits as well as the franchisee matter. To the extent that litigation becomes necessary, we believe that the subsidiaries have strong factual and legal defenses against claims that they unfairly marketed vapor products. We have two franchisor subsidiaries. Like many franchise businesses, in the ordinary course of their business, these subsidiaries are from time to time responding parties to arbitration demands brought by franchisees. We have reached an agreement to arbitrate a claim brought by a former franchisee. This matter relates to the termination of the franchise agreement by the franchisor for failure to pay franchising fees and our subsequent demand that the franchisee cease using our marks and de-image locations formerly housing the franchises. The franchisee is claiming tortious interference and conversion. We believe the franchisor’s ultimate termination of the franchise agreement for multiple uncured material defaults by the franchisee was proper. We believe we have good and valid substantive defenses against the claims and intend on vigorously defending our interests in this matter.

Income Per Share

Income Per Share	3 Months Ended
	Mar. 31, 2022
Income Per Share [Abstract]
Income Per Share	Note 16. Income Per Share The following is a reconciliation of the numerators and denominators of the basic and diluted EPS computations of net income: Three Months Ended March 31, 2022 2021 Income Shares Per Share Income Shares Per Share Basic EPS: Numerator Net income attributable to Turning Point Brands, Inc. $ 10,998 $ 11,783 Denominator Weighted average 18,257,695 $ 0.60 19,093,961 $ 0.62 Diluted EPS: Numerator Net income attributable to Turning Point Brands, Inc. $ 10,998 $ 11,783 Interest expense related to Convertible Senior Notes, net of tax 1,054 1,054 Diluted net income attributable to Turning Point Brands. Inc. $ 12,052 $ 12,837 Denominator Basic weighted average 18,257,695 19,093,961 Convertible Senior Notes 3,209,690 3,205,895 Stock options 282,125 365,211 21,749,510 $ 0.55 22,665,067 $ 0.57

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2022
Segment Information [Abstract]
Segment Information	Note 17. Segment Information In accordance with ASC 280, Segment Reporting, the Company has three reportable segments: (1) Zig-Zag Products; (2) Stoker’s Products; and (3) NewGen Products. The Zig-Zag Products segment markets and distributes (a) rolling papers, tubes, and related products; and (b) finished cigars and MYO cigar wraps. The Stoker’s Products segment (a) manufactures and markets moist snuff and (b) contracts for and markets loose leaf chewing tobacco products. The NewGen Products segment (a) markets and distributes liquid vapor products and certain other products without tobacco and/or nicotine; (b) distributes a wide assortment of products to non-traditional retail outlets via VaporBeast; and (c) markets and distributes a wide assortment of products to individual consumers via the VaporFi online platform. Products in the Zig-Zag Products and Stoker’s Products segments are distributed primarily through wholesale distributors in the United States while products in the NewGen Products segment are distributed primarily through e-commerce to non-traditional retail outlets and direct to consumers in the United States. includes the costs and assets of the Company not assigned to one of the three reportable segments such as intercompany transfers, deferred taxes, deferred financing fees, and investments in subsidiaries. NewGen The accounting policies of these segments are the same as those of the Company. Corporate costs are not directly charged to the three reportable segments in the ordinary course of operations. The Company evaluates the performance of its segments and allocates resources to them based on operating income. The tables below present financial information about reported segments: Three Months Ended March 31, 2022 2021 Net sales Zig-Zag products $ 45,672 $ 41,004 Stoker’s products 31,703 29,255 NewGen products 23,519 37,382 Total $ 100,894 $ 107,641 Gross profit Zig-Zag products $ 26,343 $ 24,896 Stoker’s products 17,686 15,892 NewGen products 7,765 12,473 Total $ 51,794 $ 53,261 Operating income (loss) Zig-Zag products $ 18,737 $ 19,437 Stoker’s products 13,506 12,255 NewGen products 678 2,006 Corporate unallocated (1)(2) (13,692 ) (9,349 ) Total $ 19,229 $ 24,349 Interest expense, net 5,196 4,486 Investment income (78 ) (25 ) Loss on extinguishment of debt - 5,706 Income before income taxes $ 14,111 $ 14,182 Capital expenditures Zig-Zag products $ 2,323 $ - Stoker’s products 464 840 NewGen products - 2 Total $ 2,787 $ 842 Depreciation and amortization Zig-Zag products $ 92 $ 114 Stoker’s products 767 635 NewGen products 475 516 Total $ 1,334 $ 1,265 (1) Includes corporate costs that are not allocated to any of the three reportable segments. (2) Includes costs related to PMTA of $1.1 million in 2022 and $0.3 million in 2021. March 31, 2022 December 31, 2021 Assets Zig-Zag products $ 227,989 $ 227,554 Stoker’s products 172,400 142,334 NewGen products 61,529 72,746 Corporate unallocated (1) 156,785 158,926 Total $ 618,703 $ 601,560 (1) Includes assets not assigned to the three reportable segments. All goodwill has been allocated to the reportable segments. Revenue Disaggregation—Sales Channel Revenues of the Zig-Zag Products and Stoker’s Products segments are primarily comprised of sales made to wholesalers while NewGen sales are made business to business and business to consumer, both online and through our corporate retail stores. NewGen net sales are broken out by sales channel below. NewGen Segment Three Months Ended March 31, 2022 2021 Business to Business $ 19,124 $ 27,257 Business to Consumer - Online 4,233 10,033 Other 162 92 Total $ 23,519 $ 37,382 Net Sales—Domestic vs. Foreign The following table shows a breakdown of consolidated net sales between domestic and foreign customers. Three Months Ended March 31, 2022 2021 Domestic $ 93,766 $ 100,127 Foreign 7,128 7,514 Total $ 100,894 $ 107,641

Dividends and Share Repurchase

Dividends and Share Repurchase	3 Months Ended
	Mar. 31, 2022
Dividends and Share Repurchase [Abstract]
Dividends and Share Repurchase	Note 18. Dividends and Share Repurchase The most recent dividend of $0.06 per common share was paid on April 8, 2022, to shareholders of record at the close of business on March 18, 2022. Dividends are considered restricted payments under the Senior Secured Notes Indenture and 2021 Revolving Credit Facility. The Company is generally permitted to make restricted payments provided that, at the time of payment, or as a result of payment, the Company is not in default on its debt covenants. Additional earnings and market capitalization restrictions limit the aggregate amount of restricted, quarterly dividends during a fiscal year. On February 25, 2020, the Company’s Board of Directors approved a $50.0 million share repurchase program, which is intended for opportunistic execution based upon a variety of factors including market dynamics. On October the Board increased the approved share repurchase program by . On February the Board increased the approve share repurchase program by . The program is subject to the ongoing discretion of the Board. The total number of shares repurchased for the months ended March was shares for a total cost of and an average price per share of remained available for share repurchases under the program at March

Description of Business and B_2

Description of Business and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2022
Description of Business and Basis of Presentation [Abstract]
Basis of Presentation	Basis of Presentation T he accompanying unaudited interim, consolidated financial statements have been prepared in accordance with the accounting practices described in the Company’s audited, consolidated financial statements as of and for the year ended December 31, 2021. In the opinion of management, the unaudited, interim, consolidated financial statements included herein contain all adjustments necessary to present fairly the financial position, results of operations, and cash flows of the Company for the periods indicated. Such adjustments, other than nonrecurring adjustments separately disclosed, are of a normal and recurring nature. The operating results for interim periods are not necessarily indicative of results to be expected for a full year or future interim periods. The unaudited, interim, consolidated financial statements should be read in conjunction with the Company’s audited, consolidated financial statements and accompanying notes as of and for the year ended December 31, 2021. The accompanying interim, consolidated financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and, accordingly, do not include all the disclosures required by generally accepted accounting principles in the United States (“GAAP”) with respect to annual financial statem

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Consolidation	Consolidation The consolidated financial statements include the accounts of the Company, its subsidiaries, all of which are wholly-owned, and variable interest entities (“VIEs”) for which the Company is considered the primary beneficiary. All significant intercompany transactions have been eliminated .
Revenue Recognition	Revenue Recognition The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606), which includes excise taxes and shipping and handling charges billed to customers, net of cash discounts for prompt payment, sales returns and incentives, upon delivery of goods to the customer – at which time the Company’s performance obligation is satisfied - at an amount that the Company expects to be entitled to in exchange for those goods in accordance with the five-step analysis outlined in Topic 606: (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) performance obligations are satisfied. The Company excludes from the transaction price, sales taxes and value-added taxes imposed at the time of sale (which do not include excise taxes on smokeless tobacco, cigars or vaping products billed to customers). The Company records an allowance for sales returns, based principally on historical volume and return rates, which is included in accrued liabilities on the consolidated balance sheets. The Company records sales incentives, which consist of consumer incentives and trade promotion activities, as a reduction in revenues (a portion of which is based on amounts estimated as being due to wholesalers, retailers and consumers at the end of the period) based principally on historical volume and utilization rates. Expected payments for sales incentives are included in accrued liabilities on the consolidated balance sheets. A further requirement of ASC 606 is for entities to disaggregate revenue recognized from contracts with customers into categories that depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The Company’s management views business performance through segments that closely resemble the performance of major product lines. Thus, the primary and most useful disaggregation of the Company’s contract revenue for decision making purposes is the disaggregation by segment which can be found in Note 17. An additional disaggregation of contract revenue by sales channel can be found within Note 17 as well.
Shipping Costs	Shipping Costs The Company records shipping costs incurred as a component of selling, general, and administrative expenses. Shipping costs incurred were approximately $5.7 million and $5.9 million for the three months ending March 31, 2022 and 2021, respectively.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value using the first-in, first-out (“FIFO”) method. Leaf tobacco is presented in current assets in accordance with standard industry practice, notwithstanding the fact that such tobaccos are carried longer than one year for the purpose of curing.
Fair Value	Fair Value GAAP establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy under GAAP are described below: ● Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets at the measurement date. ● Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. ● Level 3 – Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
Derivative Instruments	Derivative Instruments Foreign Currency Forward Contracts: The Company enters into foreign currency forward contracts to hedge a portion of its exposure to changes in foreign currency exchange rates on inventory purchase commitments. The Company accounts for its forward contracts under the provisions of ASC 815, Derivatives and Hedging. Under the Company’s policy, the Company may hedge up to 100% of its anticipated purchases of inventory in the denominated invoice currency over a forward period not to exceed twelve months. The Company may also, from time to time, hedge up to ninety percent of its non-inventory purchases in the denominated invoice currency. Forward contracts that qualify as hedges are adjusted to their fair value through other comprehensive income as determined by market prices on the measurement date, except any hedge ineffectiveness which is recognized currently in income. Gains and losses on these forward contracts are transferred from other comprehensive income into inventory as the related inventories are received and are transferred to net income as inventory is sold. Changes in fair value of any contracts that do not qualify for hedge accounting or are not designated as hedges are recognized currently in income. Interest Rate Swap Agreements: The Company enters into interest rate swap contracts to manage interest rate risk and reduce the volatility of future cash flows. The Company accounts for its interest rate swap contracts under the provisions of ASC 815, Derivatives and Hedging. Swap contracts that qualify as hedges are adjusted to their fair value through other comprehensive income as determined by market prices on the measurement date, except any hedge ineffectiveness which is recognized currently in income. Gains and losses on these swap contracts are transferred from other comprehensive income into net income upon settlement of the derivative position or at maturity of the interest rate swap contract. Changes in fair value of any contracts that do not qualify for hedge accounting or are not designated as hedges are recognized currently in income.
Risks and Uncertainties	Risks and Uncertainties Manufacturers and sellers of tobacco products are subject to regulation at the federal, state, and local levels. Such regulations include, among others, labeling requirements, limitations on advertising, and prohibition of sales to minors. The tobacco industry is likely to continue to be heavily regulated. There can be no assurance as to the ultimate content, timing, or effect of any regulation of tobacco products by any federal, state, or local legislative or regulatory body, nor can there be any assurance that any such legislation or regulation would not have a material adverse effect on the Company’s financial position, results of operations, or cash flows. In a number of states, targeted flavor bans have been proposed or enacted legislatively or by the administrative process. Depending on the number and location of such bans, that legislation or regulation could have a material adverse effect on the Company’s financial position, results of operations or cash flows. Food and Drug Administration (“FDA”) continues to consider various restrictive regulations around our products, including targeted flavor bans; however, the details, timing, and ultimate implementation of such measures remain unclear. The tobacco industry has experienced, and is experiencing, significant product liability litigation. Most tobacco liability lawsuits have been brought against manufacturers and sellers of cigarettes for injuries allegedly caused by smoking or exposure to smoke. However, several lawsuits have been brought against manufacturers and sellers of smokeless products for injuries to health allegedly caused by use of smokeless products. Typically, such claims assert that use of smokeless products is addictive and causes oral cancer. Additionally, several lawsuits have been brought against manufacturers and distributors of NewGen products due to malfunctioning devices. There can be no assurance the Company will not sustain losses in connection with such lawsuits and that such losses will not have a material adverse effect on the Company’s financial position, results of operations, or cash flows. Master Settlement Agreement (MSA): Pursuant to the Master Settlement Agreement (the “MSA”) entered into in November 1998 by most states (represented by their attorneys general acting through the National Association of Attorneys General) and subsequent states’ statutes, a “cigarette manufacturer” (which is defined to include a manufacturer of make-your-own (“MYO”) cigarette tobacco) has the option of either becoming a signatory to the MSA or opening, funding, and maintaining an escrow account to have funds available for certain potential tobacco-related liabilities with sub-accounts on behalf of each settling state. Such companies are entitled to direct the investment of the escrowed funds and withdraw any appreciation but cannot withdraw the principal for twenty-five years from the year of each annual deposit, except to withdraw funds deposited pursuant to an individual state’s escrow statute to pay a final judgement to that state’s plaintiffs in the event of such a final judgement against the Company. The Company chose to open and fund an escrow account as its method of compliance. It is the Company’s policy to record amounts on deposit in the escrow account for prior years as a non-current asset. The Company has chosen to invest a portion of the MSA escrow, from time to time, in U.S. Government securities including TIPS, Treasury Notes, and Treasury Bonds. These investments are classified as available-for-sale and carried at fair value. Realized losses are prohibited under the MSA; any investment in an unrealized loss position will be held until the value is recovered, or until maturity. Fair values for the U.S. Governmental agency obligations are Level 2 in the fair value hierarchy. The following tables show cost and estimated fair value of the assets held in the MSA account, respectively, as well as the maturities of the U.S. Governmental agency obligations held in such account for the periods indicated. As of March 31, 2022 As of December 31, 2021 Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Cash and cash equivalents $ 3,673 $ - $ - $ 3,673 $ 12,155 $ - $ - $ 12,155 U.S. Governmental agency obligations (unrealized position < 12 months) 21,452 5 (1,145 ) 20,312 19,918 4 (357 ) 19,565 U.S. Governmental agency obligations (unrealized position > 12 months) 6,948 - (696 ) 6,252 - - - - $ 32,073 $ 5 $ (1,841 ) $ 30,237 $ 32,073 $ 4 $ (357 ) $ 31,720 As of March 31, Less than one year $ - One to five years 7,443 Five to ten years 20,001 Greater than ten years 956 Total $ 28,400 The following shows the amount of deposits by sales year for the MSA escrow account: Deposits as of Sales Year March 31, 2022 December 31, 2021 1999 $ 211 $ 211 2000 1,017 1,017 2001 1,673 1,673 2002 2,271 2,271 2003 4,249 4,249 2004 3,714 3,714 2005 4,553 4,553 2006 3,847 3,847 2007 4,167 4,167 2008 3,364 3,364 2009 1,619 1,619 2010 406 406 2011 193 193 2012 199 199 2013 173 173 2014 143 143 2015 101 101 2016 91 91 2017 82 82 Total $ 32,073 $ 32,073 Food and Drug Administration (FDA): On June 22, 2009, the Family Smoking Prevention and Tobacco Control Act (the “ FSPTCA On August 8, 2016, the FDA deeming regulation became effective. The deeming regulation gave the FDA the authority to also regulate cigars, pipe tobacco, e-cigarettes, vaporizers, and e-liquids as “deemed” tobacco products under the FSPTCA. The FDA assesses tobacco product user fees on six c lasses of regulated tobacco products and computes user fees using a methodology similar to the methodology used by the U.S Department of Agriculture to compute the Tobacco Transition Payment Program (“TTPP,” also known as the “Tobacco Buyout”) assessment. First, the total, annual, congressionally established user fee assessment is allocated among the various classes of tobacco products using the federal excise tax weighted market share of tobacco products subject to regulation. Then, the assessment for each class of tobacco products is divided among individual manufacturers and importers In August 2016, the FDA’s regulatory authority under the Tobacco Control Act (the “TCA”) Under the deeming regulations, the FDA has responsibility for conducting premarket review of “new tobacco products”—defined as those products not commercially marketed in the United States as of February 15, 2007. There are three pathways for obtaining premarket authorization, including submission of a premarket tobacco product application (“PMTA”). We submitted premarket filings prior to the September 9, 2020 deadline for certain of our products and have continued to supplement these applications with additional information. A successful PMTA must demonstrate that the subject product is “appropriate for the protection of public health,” taking into account the effect of the marketing of the product on all sub-populations while a Substantial Equivalence Report must demonstrate that a new product either has the same characteristics as its predicate product or different characteristics, but does not raise different questions of public health. The FDA has indicated its enforcement priority is those applicants who have received negative action on their application, such as a Marketing Denial Order or Refuse to File notification and who continue to illegally sell those unauthorized products, as well as products for which manufacturers failed to submit a marketing application. The FDA has issued a number of proposed rules related to premarket filings; however, those rules were not finalized prior to the September 9, 2020, deadline. On October 5, 2021, the FDA finalized two rules related to the Substantial Equivalence process and the Premarket Tobacco Product Application process, respectively, which both become effective November 4, 2021. Both final rules (collectively, the “Rules”) indicate that any new or additional requirements will not retroactively apply to currently pending PMTAs; however, the information outlined in the rule remains important to the FDA’s substantive review of an application. We believe we have products that meet the Rules and have filed premarket filings supporting a showing of the respective required standards. However, there is no assurance that the FDA’s guidance or regulations will not change, that the FDA will not prioritize its enforcement in a manner that negatively affects our pending applications, or that unforeseen circumstances will not arise that prevent us from sufficiently supplementing or completing our applications or otherwise increase the amount of time and money we are required to spend to receive all necessary marketing orders. Although we filed many premarket applications in a timely manner, no assurance can be given that the applications will ultimately be successful. This may result in the prioritization of supplementing or completing applications for high priority SKUs in our inventory position, which could adversely impact future revenues generated by lower priority SKUs. In addition, we currently distribute many third-party manufactured vapor products for which we will be completely dependent on the manufacturer complying with the premarket filing requirements. There can be no assurance that these third-party products will receive a marketing order or otherwise remain in compliance with relevant legal requirements. While we will take measures to pursue regulatory compliance for our own privately-branded or proprietary vape products that compete with these third-party products, there is no assurance that such proprietary products would be as successful in the marketplace or can fully displace third-party products that are currently being distributed by us, which could adversely affect our results of operations and liquidity. For a period of time after the filing deadline, we expect there to be a lack of enforcement, which may adversely affect our ability to compete in the marketplace against those who continue to sell unauthorized products. On April 29, 2021, the FDA announced plans to propose two tobacco product standards related to combusted tobacco products: (1) a ban on menthol as a characterizing flavor in cigarettes; and (2) a ban on all characterizing flavors (including menthol) in cigars. These product standards are required to go through the formal rulemaking process where we would have the opportunity to comment on the proposed rule with regard to any impact on any of our products. The FDA’s policy on these and other regulated products may change or expand over time in ways not yet known and may significantly impact our products or our premarket filings. On March 15, 2022, the Consolidated Appropriations Act of 2022 was signed into law. This law included a new provision bringing non-tobacco nicotine products (“NTN Products”), including synthetic nicotine, under the jurisdiction of the FDA Center for Tobacco Products. This law took effect April 14, 2022, and subjects NTN Products to the same requirements as tobacco-derived products, including not selling these products to persons under 21 years of age, not marketing these products as modified risk tobacco products, and not distributing free samples of these products. Additionally, NTN Products on the market between March 15, 2022, and April 14, 2022, must file a PMTA by May 14, 2022. NTN Products subject of a timely-filed PMTA, and not in receipt of a negative action, may remain on the market until July 13, 2022. After July 13, 2022, these products are subject to enforcement. We have been compiling premarket filings for certain of our NTN Products and will submit these filings ahead of the May 14, 2022, deadline. After the deadline passes, we will continue to supplement these filings with additional information; however, there can be no guarantee that FDA will accept such amendments or, similar to other filings, that the applications will meet the standard of “appropriate for the protection of public health.” We also expect that for a period of time after the filing deadline, there may be a lack of enforcement, which may adversely impact our ability to compete in the marketplace against those who continue to sell unauthorized products. Prevent All Cigarette Trafficking Act (“PACT Act”): On December 27, 2020, President Trump signed the Further Consolidated Appropriations Act, 2021, into law. This law included an amendment to the Jenkins Act expanding the definition of “cigarette” to include “electronic nicotine delivery systems,” or ENDS, and required that the United States Postal Service (USPS) promulgate regulations clarifying the applicability of the prohibition on delivery sales of cigarettes to ENDS. USPS issued its final rule on October 21, 2021. We have received appropriate shipping exemptions from carrier services we use to carry the affected freight. Failure to comply with the PACT Act could result in significant financial or criminal penalties. To the extent we are unable to respond to, or comply with, these new requirements, we could lose our shipping exemptions, be subject to civil or criminal penalties, or there could be a material adverse effect on our business, results of operations and financial condition.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Fair Value of MSA Escrow Account	Fair values for the U.S. Governmental agency obligations are Level 2 in the fair value hierarchy. The following tables show cost and estimated fair value of the assets held in the MSA account, respectively, as well as the maturities of the U.S. Governmental agency obligations held in such account for the periods indicated. As of March 31, 2022 As of December 31, 2021 Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Cash and cash equivalents $ 3,673 $ - $ - $ 3,673 $ 12,155 $ - $ - $ 12,155 U.S. Governmental agency obligations (unrealized position < 12 months) 21,452 5 (1,145 ) 20,312 19,918 4 (357 ) 19,565 U.S. Governmental agency obligations (unrealized position > 12 months) 6,948 - (696 ) 6,252 - - - - $ 32,073 $ 5 $ (1,841 ) $ 30,237 $ 32,073 $ 4 $ (357 ) $ 31,720
Maturities of U.S. Governmental Agency Obligations	As of March 31, Less than one year $ - One to five years 7,443 Five to ten years 20,001 Greater than ten years 956 Total $ 28,400
Deposits by Sales Year for MSA Escrow Account	The following shows the amount of deposits by sales year for the MSA escrow account: Deposits as of Sales Year March 31, 2022 December 31, 2021 1999 $ 211 $ 211 2000 1,017 1,017 2001 1,673 1,673 2002 2,271 2,271 2003 4,249 4,249 2004 3,714 3,714 2005 4,553 4,553 2006 3,847 3,847 2007 4,167 4,167 2008 3,364 3,364 2009 1,619 1,619 2010 406 406 2011 193 193 2012 199 199 2013 173 173 2014 143 143 2015 101 101 2016 91 91 2017 82 82 Total $ 32,073 $ 32,073

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2022
Acquisitions [Abstract]
Acquisition of Direct Value Wholesale	In April 2021, Turning Point Brands Canada, a VIE for which the Company is considered the primary beneficiary, purchased 100% of the equity interests of Westhem Ventures LTD d/b/a Direct Value Wholesale (“DVW”) for $3.9 million, net of cash acquired, with $3.5 million paid in cash at closing and $0.5 million in accrued consideration to be paid during 2021. DVW is a Canadian distribution entity that operates in markets not primarily served by Turning Point Brands Canada. The acquisition expands Turning Point Brands Canada’s markets in Canada. On April 13, 2021, in connection with the acquisition of DVW, the Company provided a $3.7 million unsecured loan to Turning Point Brands Canada bearing interest at 8% per annum and maturing April 13, 2023. The unsecured loan is eliminated in the consolidation of Turning Point Brands Canada. As of March 31, 2022, Turning Point Brands Canada had not completed the accounting for the acquisition. The following table summarizes the consideration transferred and calculation of goodwill based on excess of the acquisition price over the estimated fair value of the identifiable net assets acquired and are based on management’s preliminary estimates: Total consideration transferred $ 3,462 Adjustments to consideration transferred: Cash acquired (43 ) Accrued consideration 472 Adjusted consideration transferred 3,891 Assets acquired: Working capital (primarily AR and inventory) 1,334 Fixed assets and Other long term assets 27 Net assets acquired $ 1,361 Goodwill $ 2,530

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2022
Inventories [Abstract]
Inventories	The components of inventories are as follows: March 31, 2022 December 31, 2021 Raw materials and work in process $ 7,483 $ 6,936 Leaf tobacco 47,733 35,900 Finished goods - Zig-Zag Products 28,928 25,663 Finished goods - Stoker’s Products 11,142 8,959 Finished goods - NewGen products 9,167 8,591 Other 1,405 1,558 Inventories $ 105,858 $ 87,607

Other Current Assets (Tables)

Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Other Current Assets [Abstract]
Other Current Assets	Other current assets consist of: March 31, 2022 December 31, 2021 Inventory deposits $ 9,245 $ 12,091 Insurance deposit 3,000 3,000 Other 13,418 11,655 Total $ 25,663 $ 26,746

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant, and Equipment [Abstract]
Property, Plant, and Equipment	Property, plant, and equipment consists of: March 31, 2022 December 31, 2021 Land $ 22 $ 22 Buildings and improvements 3,096 3,096 Leasehold improvements 5,389 5,374 Machinery and equipment 22,322 19,591 Furniture and fixtures 9,380 9,402 Gross property, plant and equipment 40,209 37,485 Accumulated depreciation (19,642 ) (18,835 ) Net property, plant and equipment $ 20,567 $ 18,650

Other Assets (Tables)

Other Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Other Assets [Abstract]
Other Assets	Other assets consist of: March 31, 2022 December 31, 2021 Equity investments $ 25,617 $ 25,649 Debt security investment 8,000 8,000 Other 1,400 1,750 Total $ 35,017 $ 35,399

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Accrued Liabilities [Abstract]
Accrued Liabilities	Accrued liabilities consist of: March 31, 2022 December 31, 2021 Accrued payroll and related items $ 4,768 $ 6,974 Customer returns and allowances 6,257 6,497 Taxes payable 5,269 2,053 Lease liabilities 3,034 2,976 Accrued interest 2,724 7,318 Other 7,869 7,119 Total $ 29,921 $ 32,937

Notes Payable and Long-Term D_2

Notes Payable and Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Payable and Long-Term Debt [Abstract]
Notes Payable and Long-Term Debt	Notes payable and long-term debt consists of the following in order of preference: March 31, 2022 December 31, 2021 Senior Secured Notes $ 250,000 $ 250,000 Convertible Senior Notes 172,500 172,500 Gross notes payable and long-term debt 422,500 422,500 Less deferred finance charges (7,709 ) (8,328 ) Notes payable and long-term debt $ 414,791 $ 414,172

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Components of Lease Expense	The components of lease expense consisted of the following: Three Months Ended March 31, 2022 2021 Operating lease cost Cost of sales $ 227 $ 225 Selling, general and administrative 690 752 Variable lease cost (1) 112 205 Short-term lease cost 14 11 Sublease income - (30 ) Total $ 1,043 $ 1,163 (1) Variable lease cost includes elements of a contract that do not represent a good or service but for which the lessee is responsible for paying.
Operating Lease Assets and Liabilities	March 31, 2022 December 31, 2021 Assets: Right of use assets $ 14,405 $ 15,053 Total lease assets $ 14,405 $ 15,053 Liabilities: Current lease liabilities $ 3,034 $ 2,976 Long-term lease liabilities 12,625 13,336 Total lease liabilities $ 15,659 $ 16,312 (2) Reported within accrued liabilities on the balance sheet
Operating Lease Weighted-Average Remaining Lease Term and Discount Rate	As of March 31, 2022 2021 Weighted-average remaining lease term - operating leases 6.5 years 7.1 years Weighted-average discount rate - operating leases 4.88 % 4.93 %
Maturities of Lease Liabilities	As of March 31, 2022, maturities of lease liabilities consisted of the following: March 31, 2022 2022 $ 2,775 2023 3,635 2024 2,460 2025 2,145 2026 2,085 Years thereafter 5,343 Total lease payments $ 18,443 Less: Imputed interest 2,784 Present value of lease liabilities $ 15,659

Share Incentive Plans (Tables)

Share Incentive Plans (Tables)	3 Months Ended
	Mar. 31, 2022
Share Incentive Plans [Abstract]
Stock Option Activity	Stock option activity for the 2006, 2015 and 2021 Plans is summarized below: Stock Option Shares Weighted Average Exercise Price Weighted Average Grant Date Fair Value Outstanding, December 31, 2020 711,060 $ 19.58 $ 6.42 Granted 119,500 50.93 13.58 Exercised (202,768 ) 10.22 6.35 Forfeited (7,957 ) 33.22 9.63 Outstanding, December 31, 2021 619,835 28.51 8.70 Granted 100,000 30.46 10.23 Exercised (25,166 ) 16.14 4.89 Forfeited (7,217 ) 29.53 8.13 Outstanding, March 31 2022 687,452 $ 29.23 $ 9.07
Assumptions for Options Granted Under 2015 Plan	The following table outlines the assumptions based on the number of options granted under the 2015 Plan. February 10, 2017 May 17, 2017 March 7, 2018 March 20, 2019 October 24, 2019 March 18, 2020 February 18, 2021 May 3, 2021 Number of options granted 40,000 93,819 98,100 155,780 25,000 155,000 100,000 12,000 Options outstanding at March 31 2022 20,000 46,483 58,667 142,284 25,000 94,612 94,529 12,000 Number exercisable at March 31 2022 20,000 46,483 58,667 142,284 25,000 62,148 39,386 4,080 Exercise price $ 13.00 $ 15.41 $ 21.21 $ 47.58 $ 20.89 $ 14.85 $ 51.75 $ 47.76 Remaining lives 4.87 5.13 5.94 6.98 7.57 7.97 8.89 9.10 Risk free interest rate 1.89 % 1.76 % 2.65 % 2.34 % 1.58 % 0.79 % 0.56 % 0.84 % Expected volatility 27.44 % 26.92 % 28.76 % 30.95 % 31.93 % 35.72 % 28.69 % 29.03 % Expected life 6.000 6.000 6.000 6.000 6.000 6.000 6.000 6.000 Dividend yield - - 0.83 % 0.42 % 0.95 % 1.49 % 0.55 % 0.59 % Fair value at grant date $ 3.98 $ 4.60 $ 6.37 $ 15.63 $ 6.27 $ 4.41 $ 13.77 $ 13.06 The following table outlines the assumptions based on the number of options granted under the 2021 Plan. May 17, 2021 March 14, 2022 Number of options granted 7,500 100,000 Options outstanding at March 31 2022 7,500 100,000 Number exercisable at March 31 2022 2,550 - Exercise price $ 45.05 $ 30.46 Remaining lives 9.13 9.96 Risk free interest rate 0.84 % 2.10 % Expected volatility 31.50 % 35.33 % Expected life 6.000 6.000 Dividend yield 0.63 % 1.01 % Fair value at grant date $ 13.23 $ 10.23
PRSU Activity	PRSUs are restricted stock units subject to both performance-based and service-based vesting conditions. The number of shares of TPB Common Stock a recipient will receive upon vesting of a PRSU will be calculated by reference to certain performance metrics related to the Company’s performance over a five-year period. PRSUs will vest on the measurement date, which is no more than days after the performance period provided the applicable service and performance conditions are satisfied. As of March 31, 2022 there are PRSUs outstanding, all of which are unvested. The following table outlines the PRSUs granted and outstanding as of March 31, 2022 March 7, 2018 March 20, 2019 July 19, 2019 March 18, 2020 December 28, 2020 February 18, 2021 March 14, 2022 Number of PRSUs granted 96,000 92,500 88,582 94,000 88,169 100,000 49,996 PRSUs outstanding at March 31 2022 89,600 77,380 21,342 86,610 58,779 93,840 49,996 Fair value as of grant date $ 21.21 $ 47.58 $ 52.15 $ 14.85 $ 46.42 $ 51.75 $ 30.46 Remaining lives 0.75 1.75 0.75 2.75 1.75 3.75 4.75
RSU Activity	The Company has granted 87,367 RSUs which vest over one May 4, 2021 July 23, 2021 March 14, 2022 March 14, 2022 Number of RSUs granted 7,478 1,159 50,004 28,726 RSUs outstanding at March 31, 2022 7,478 1,159 50,004 28,726 Fair value as of grant date $ 47.86 $ 51.81 $ 30.46 $ 30.46 Remaining lives 0.09 0.31 4.75 2.75

Income Per Share (Tables)

Income Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Income Per Share [Abstract]
Basic and Diluted Net Income per Share	The following is a reconciliation of the numerators and denominators of the basic and diluted EPS computations of net income: Three Months Ended March 31, 2022 2021 Income Shares Per Share Income Shares Per Share Basic EPS: Numerator Net income attributable to Turning Point Brands, Inc. $ 10,998 $ 11,783 Denominator Weighted average 18,257,695 $ 0.60 19,093,961 $ 0.62 Diluted EPS: Numerator Net income attributable to Turning Point Brands, Inc. $ 10,998 $ 11,783 Interest expense related to Convertible Senior Notes, net of tax 1,054 1,054 Diluted net income attributable to Turning Point Brands. Inc. $ 12,052 $ 12,837 Denominator Basic weighted average 18,257,695 19,093,961 Convertible Senior Notes 3,209,690 3,205,895 Stock options 282,125 365,211 21,749,510 $ 0.55 22,665,067 $ 0.57

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Information [Abstract]
Financial Information of Reportable Segments	The tables below present financial information about reported segments: Three Months Ended March 31, 2022 2021 Net sales Zig-Zag products $ 45,672 $ 41,004 Stoker’s products 31,703 29,255 NewGen products 23,519 37,382 Total $ 100,894 $ 107,641 Gross profit Zig-Zag products $ 26,343 $ 24,896 Stoker’s products 17,686 15,892 NewGen products 7,765 12,473 Total $ 51,794 $ 53,261 Operating income (loss) Zig-Zag products $ 18,737 $ 19,437 Stoker’s products 13,506 12,255 NewGen products 678 2,006 Corporate unallocated (1)(2) (13,692 ) (9,349 ) Total $ 19,229 $ 24,349 Interest expense, net 5,196 4,486 Investment income (78 ) (25 ) Loss on extinguishment of debt - 5,706 Income before income taxes $ 14,111 $ 14,182 Capital expenditures Zig-Zag products $ 2,323 $ - Stoker’s products 464 840 NewGen products - 2 Total $ 2,787 $ 842 Depreciation and amortization Zig-Zag products $ 92 $ 114 Stoker’s products 767 635 NewGen products 475 516 Total $ 1,334 $ 1,265 (1) Includes corporate costs that are not allocated to any of the three reportable segments. (2) Includes costs related to PMTA of $1.1 million in 2022 and $0.3 million in 2021. March 31, 2022 December 31, 2021 Assets Zig-Zag products $ 227,989 $ 227,554 Stoker’s products 172,400 142,334 NewGen products 61,529 72,746 Corporate unallocated (1) 156,785 158,926 Total $ 618,703 $ 601,560 (1) Includes assets not assigned to the three reportable segments. All goodwill has been allocated to the reportable segments.
Revenue Disaggregation - Sales Channel	Revenues of the Zig-Zag Products and Stoker’s Products segments are primarily comprised of sales made to wholesalers while NewGen sales are made business to business and business to consumer, both online and through our corporate retail stores. NewGen net sales are broken out by sales channel below. NewGen Segment Three Months Ended March 31, 2022 2021 Business to Business $ 19,124 $ 27,257 Business to Consumer - Online 4,233 10,033 Other 162 92 Total $ 23,519 $ 37,382
Net Sales - Domestic and Foreign	The following table shows a breakdown of consolidated net sales between domestic and foreign customers. Three Months Ended March 31, 2022 2021 Domestic $ 93,766 $ 100,127 Foreign 7,128 7,514 Total $ 100,894 $ 107,641

Description of Business and B_3

Description of Business and Basis of Presentation (Details) Outlet in Thousands	3 Months Ended
	Mar. 31, 2022OutletSegment
Description of Business and Basis of Presentation [Abstract]
Number of reportable segments | Segment	3
Number of retail outlets in North America | Outlet	215

Summary of Significant Accoun_4

Summary of Significant Accounting Policies, Shipping Costs (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Shipping Costs [Abstract]
Shipping costs	$ 5.7	$ 5.9

Summary of Significant Accoun_5

Summary of Significant Accounting Policies, Derivative Instruments (Details) - Maximum [Member]	3 Months Ended
	Mar. 31, 2022
Derivative Instruments [Abstract]
Percentage of anticipated purchases of inventory that may be hedged	100.00%
Term of hedge	12 months
Percentage of non-inventory purchases that may be hedged	90.00%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies, Master Settlement Agreement (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Master Settlement Agreement [Abstract]
Term for restricted withdrawal of principal from MSA escrow account	25 years
Fair Value of MSA Escrow Account [Abstract]
Cost	$ 32,073	$ 32,073
Gross unrealized gains	5	4
Gross unrealized losses	(1,841)	(357)
Estimated fair value	30,237	31,720
Maturities of U.S. Governmental Agency Obligations [Abstract]
Less than one year	0
One to five years	7,443
Five to ten years	20,001
Greater than ten years	956
Total	28,400
Master Settlement Agreement Escrow Account by Sales Year [Abstract]
1999	211	211
2000	1,017	1,017
2001	1,673	1,673
2002	2,271	2,271
2003	4,249	4,249
2004	3,714	3,714
2005	4,553	4,553
2006	3,847	3,847
2007	4,167	4,167
2008	3,364	3,364
2009	1,619	1,619
2010	406	406
2011	193	193
2012	199	199
2013	173	173
2014	143	143
2015	101	101
2016	91	91
2017	82	82
Total	32,073	32,073
Cash and Cash Equivalents [Member]
Fair Value of MSA Escrow Account [Abstract]
Cost	3,673	12,155
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Estimated fair value	3,673	12,155
U. S. Governmental Agency Obligations [Member] | Unrealized Position less than 12 Months [Member]
Fair Value of MSA Escrow Account [Abstract]
Cost	21,452	19,918
Gross unrealized gains	5	4
Gross unrealized losses	(1,145)	(357)
Estimated fair value	20,312	19,565
U. S. Governmental Agency Obligations [Member] | Unrealized Position more than 12 Months [Member]
Fair Value of MSA Escrow Account [Abstract]
Cost	6,948	0
Gross unrealized gains	0	0
Gross unrealized losses	(696)	0
Estimated fair value	$ 6,252	$ 0

Summary of Significant Accoun_7

Summary of Significant Accounting Policies, Food and Drug Administration (Details)	3 Months Ended
	Mar. 31, 2022ClassPathwayCategoryStandard	Oct. 05, 2021Rule
Food and Drug Administration [Abstract]
Number of categories of tobacco products regulated by the FDA | Category	4
Number of classes of regulated tobacco products on which user fees are assessed | Class	6
Number of pathways for obtaining premarket authorization | Pathway	3
Number of rules finalized by the FDA | Rule		2
Number of proposed tobacco product standards related to combusted tobacco products | Standard	2

Acquisitions, Unitabac (Details

Acquisitions, Unitabac (Details) - Unitabac [Member] $ in Millions	1 Months Ended
	Jul. 31, 2021USD ($)
Acquisitions [Abstract]
Total consideration transferred	$ 10.7
Cash paid for assets acquired	9.6
Capitalized transaction costs	1.1
Inventory acquired	0.7
Intellectual Property [Member]
Acquisitions [Abstract]
Indefinite-lived intangible asset acquired	$ 10

Acquisitions, Direct Value Whol

Acquisitions, Direct Value Wholesale (Details) - USD ($) $ in Thousands	1 Months Ended
	Apr. 30, 2021	Mar. 31, 2022	Dec. 31, 2021	Apr. 13, 2021
Assets Acquired [Abstract]
Goodwill		$ 162,323	$ 162,333
Direct Value Wholesale [Member]
Acquisitions [Abstract]
Equity interest	100.00%
Cash paid for acquisition	$ 3,500
Purchase Price [Abstract]
Total consideration transferred	3,462
Adjustments to Consideration Transferred [Abstract]
Cash acquired	(43)
Accrued consideration	472
Adjusted consideration transferred	3,891
Assets Acquired [Abstract]
Working capital (primarily AR and inventory)	1,334
Fixed assets and other long term assets	27
Net assets acquired	1,361
Goodwill	$ 2,530
Turning Point Brands Canada [Member]
Acquisitions [Abstract]
Unsecured loan				$ 3,700
Interest rate				8.00%

Acquisitions, Turning Point Bra

Acquisitions, Turning Point Brands Canada (Details) $ in Millions	1 Months Ended
	Jul. 31, 2021USD ($)
Non-Controlling Interest [Member]
Acquisitions [Abstract]
Acquisition of additional ownership interest	$ (1.1)
Additional Paid-In Capital [Member]
Acquisitions [Abstract]
Acquisition of additional ownership interest	(1.1)
Turning Point Brands Canada [Member]
Acquisitions [Abstract]
Payment for investment	$ 2.3
Ownership interest	65.00%

Derivative Instruments (Details

Derivative Instruments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Mar. 31, 2018
Derivative Instruments [Abstract]
Settlement of interest rate swaps	$ 0	$ 3,573
Maximum [Member]
Derivative Instruments [Abstract]
Percentage of anticipated purchases of inventory that may be hedged	100.00%
Term of hedge	12 months
Percentage of non-inventory purchases that may be hedged	90.00%
Foreign Currency [Member]
Derivative Instruments [Abstract]
Notional amount	$ 0		$ 0
Interest Rate Swaps [Member]
Derivative Instruments [Abstract]
Notional amount				$ 70,000
Settlement of interest rate swaps		$ 3,600
Interest Rate Swaps [Member] | LIBOR [Member]
Derivative Instruments [Abstract]
Interest rate percentage	2.755%

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Feb. 11, 2021	Jul. 31, 2019
Fair Value of Financial Instruments [Abstract]
Note payable	$ 422,500	$ 422,500
Senior Secured Notes [Member]
Fair Value of Financial Instruments [Abstract]
Interest rate	5.625%
Face amount	$ 250,000	250,000	$ 250,000
Note payable	$ 250,000	250,000
Convertible Senior Notes [Member]
Fair Value of Financial Instruments [Abstract]
Interest rate	2.50%
Face amount				$ 172,500
Note payable	$ 172,500	172,500
Fair Value [Member] | Convertible Senior Notes [Member]
Fair Value of Financial Instruments [Abstract]
Long-term debt	$ 160,900	$ 159,800

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventories [Abstract]
Raw materials and work in process	$ 7,483	$ 6,936
Leaf tobacco	47,733	35,900
Other	1,405	1,558
Inventories	105,858	87,607
Inventory valuation allowance	5,400	7,700
Zig-Zag Products [Member]
Inventories [Abstract]
Finished goods	28,928	25,663
Stoker's Products [Member]
Inventories [Abstract]
Finished goods	11,142	8,959
NewGen Products [Member]
Inventories [Abstract]
Finished goods	$ 9,167	$ 8,591

Other Current Assets (Details)

Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Other Current Assets [Abstract]
Inventory deposits	$ 9,245	$ 12,091
Insurance deposit	3,000	3,000
Other	13,418	11,655
Total	$ 25,663	$ 26,746

Property, Plant, and Equipmen_2

Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant, and Equipment [Abstract]
Property, plant and equipment	$ 40,209	$ 37,485
Accumulated depreciation	(19,642)	(18,835)
Net property, plant and equipment	20,567	18,650
Land [Member]
Property, Plant, and Equipment [Abstract]
Property, plant and equipment	22	22
Buildings and Improvements [Member]
Property, Plant, and Equipment [Abstract]
Property, plant and equipment	3,096	3,096
Leasehold Improvements [Member]
Property, Plant, and Equipment [Abstract]
Property, plant and equipment	5,389	5,374
Machinery and Equipment [Member]
Property, Plant, and Equipment [Abstract]
Property, plant and equipment	22,322	19,591
Furniture and Fixtures [Member]
Property, Plant, and Equipment [Abstract]
Property, plant and equipment	$ 9,380	$ 9,402

Other Assets (Details)

Other Assets (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	Jul. 31, 2021	Apr. 30, 2021	Mar. 31, 2022	Dec. 31, 2021
Other Assets [Abstract]
Equity investments			$ 25,617	$ 25,649
Debt security investment			8,000	8,000
Other			1,400	1,750
Total			$ 35,017	35,399
Docklight Brands, Inc. [Member]
Other Assets [Abstract]
Payment for investment		$ 8,700
Old Pal Holding Company LLC [Member]
Other Assets [Abstract]
Payment for investment	$ 8,000
Interest rate			3.00%
Extension period for maturity date			1 year
Weighted average interest rate			3.00%
Old Pal Holding Company LLC [Member] | Other Current Assets [Member]
Other Assets [Abstract]
Accrued interest receivable			$ 200	$ 100

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands		Mar. 31, 2022	Dec. 31, 2021
Accrued Liabilities [Abstract]
Accrued payroll and related items		$ 4,768	$ 6,974
Customer returns and allowances		6,257	6,497
Taxes payable		5,269	2,053
Lease liabilities	[1]	3,034	2,976
Accrued interest		2,724	7,318
Other		7,869	7,119
Total		$ 29,921	$ 32,937
[1]	Reported within accrued liabilities on the balance sheet

Notes Payable and Long-Term D_3

Notes Payable and Long-Term Debt, Summary of Notes Payable and Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Notes Payable and Long-Term Debt [Abstract]
Gross notes payable and long-term debt	$ 422,500	$ 422,500
Less deferred finance charges	(7,709)	(8,328)
Net notes payable and long-term debt	414,791	414,172
Senior Secured Notes [Member]
Notes Payable and Long-Term Debt [Abstract]
Gross notes payable and long-term debt	250,000	250,000
Convertible Senior Notes [Member]
Notes Payable and Long-Term Debt [Abstract]
Gross notes payable and long-term debt	$ 172,500	$ 172,500

Notes Payable and Long-Term D_4

Notes Payable and Long-Term Debt, Senior Secured Notes (Details) - Senior Secured Notes [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Feb. 11, 2021
Notes Payable and Long-Term Debt [Abstract]
Face amount	$ 250	$ 250	$ 250
Interest rate	5.625%
Maturity date	Feb. 15, 2026
Guarantee threshold amount for obligations	$ 15
Redemption price as a percentage of principal amount for principal redeemed	100.00%
Percentage of principal amount that can be redeemed with net cash proceeds from certain equity offerings	40.00%
Redemption price as a percentage of principal amount for principal amount that can be redeemed with net cash proceeds from certain equity offerings	105.625%
Percentage of principal amount that must remain outstanding in order to redeem 40% of principal amount with net cash proceeds from certain equity offerings	50.00%
Period in which 10% of principal amount can be redeemed once	12 months
Percentage of principal amount that can be redeemed once in any twelve-month period	10.00%
Redemption price as a percentage of principal amount for principal amount that can be redeemed once in any twelve-month period	103.00%
Redemption price as a percentage of principal amount for principal amount that can be redeemed if the Company experiences a change in control	101.00%
Debt issuance costs			$ 6.4

Notes Payable and Long-Term D_5

Notes Payable and Long-Term Debt, 2021 Revolving Credit Facility (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2023	Feb. 11, 2021USD ($)
2021 Revolving Credit Facility [Member]
Notes Payable and Long-Term Debt [Abstract]
Maximum borrowing capacity			$ 25
Amount drawn under credit facility	$ 0
Letters of credit outstanding	$ 3.6
Maturity date	Aug. 11, 2025
Period prior to maturity date of Convertible Senior Notes	91 days
Consolidated Leverage Ratio	5.50
Exclusion threshold for letters of credit	$ 5
Threshold percentage of total commitments outstanding	35.00%
Debt issuance costs	$ 0.5
2021 Revolving Credit Facility [Member] | Plan [Member]
Notes Payable and Long-Term Debt [Abstract]
Consolidated Leverage Ratio		5.25
2021 Revolving Credit Facility [Member] | Eurodollar [Member]
Notes Payable and Long-Term Debt [Abstract]
Margin on variable rate	3.50%
Letters of Credit [Member]
Notes Payable and Long-Term Debt [Abstract]
Maximum borrowing capacity			$ 10

Notes Payable and Long-Term D_6

Notes Payable and Long-Term Debt, 2018 First Lien Credit Facility (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Notes Payable and Long-Term Debt [Abstract]
Payment of term loan	$ 0	$ 130,000
Loss on extinguishment of debt	$ 0	(5,706)
2018 First Lien Credit Facility [Member]
Notes Payable and Long-Term Debt [Abstract]
Payment of term loan		130,000
Loss on extinguishment of debt		$ (5,700)
2018 Revolving Credit Facility [Member] | LIBOR [Member] | Minimum [Member]
Notes Payable and Long-Term Debt [Abstract]
Margin on variable rate	2.75%
2018 Revolving Credit Facility [Member] | LIBOR [Member] | Maximum [Member]
Notes Payable and Long-Term Debt [Abstract]
Margin on variable rate	3.50%
2018 First Lien Term Loan [Member] | LIBOR [Member] | Minimum [Member]
Notes Payable and Long-Term Debt [Abstract]
Margin on variable rate	2.75%
2018 First Lien Term Loan [Member] | LIBOR [Member] | Maximum [Member]
Notes Payable and Long-Term Debt [Abstract]
Margin on variable rate	3.50%

Notes Payable and Long-Term D_7

Notes Payable and Long-Term Debt, Convertible Senior Notes (Details)	1 Months Ended	3 Months Ended
	Jul. 31, 2019USD ($)	Mar. 31, 2022USD ($)shares$ / shares
Notes Payable and Long-Term Debt [Abstract]
Strike price (in dollars per share) | $ / shares		53.74
Cap price (in dollars per share) | $ / shares		82.86
Payment for cost of capped call transactions | $	$ 20,530,000
Convertible Senior Notes [Member]
Notes Payable and Long-Term Debt [Abstract]
Face amount | $	172,500,000
Interest rate		2.50%
Maturity date		Jul. 15, 2024
Shares issued upon conversion (in shares) | shares		3,209,690
Conversion rate		18.607
Principal amount of notes to be converted | $		$ 1,000
Conversion price (in dollars per share) | $ / shares		$ 53.74
Pre-determined threshold value for adjusting conversion price as a result of dividends paid (in dollars per share) | $ / shares		$ 0.04
Debt issuance costs | $	$ 5,900,000

Notes Payable and Long-Term D_8

Notes Payable and Long-Term Debt, Promissory Note (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Jun. 10, 2020
Notes Payable and Long-Term Debt [Abstract]
Gain on extinguishment of debt	$ 0		$ (5,706)
Promissory Note [Member]
Notes Payable and Long-Term Debt [Abstract]
Face amount				$ 10,000
Interest rate	7.50%
Repayment of note		$ 9,600
Gain on extinguishment of debt		$ 400

Notes Payable and Long-Term D_9

Notes Payable and Long-Term Debt, Unsecured Loan (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Apr. 17, 2020
Notes Payable and Long-Term Debt [Abstract]
Gain on extinguishment of debt	$ 0		$ (5,706)
Unsecured Loan [Member]
Notes Payable and Long-Term Debt [Abstract]
Face amount				$ 7,500
Maturity date	Apr. 17, 2022
Interest rate	1.00%
Gain on extinguishment of debt		$ 7,500

Leases (Details)

Leases (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Components of Lease Expense [Abstract]
Variable lease cost	[1]	$ 112	$ 205
Short-term lease cost		14	11
Sublease income		0	(30)
Total operating lease cost		1,043	$ 1,163
Assets [Abstract]
Right of use assets		14,405		$ 15,053
Liabilities [Abstract]
Current lease liabilities	[2]	$ 3,034		$ 2,976
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]		Accrued Liabilities, Current		Accrued Liabilities, Current
Long-term lease liabilities		$ 12,625		$ 13,336
Total lease liabilities		$ 15,659		16,312
Weighted-Average Remaining Lease Term and Discount Rate [Abstract]
Weighted-average remaining lease term - operating leases		6 years 6 months	7 years 1 month 6 days
Weighted-average discount rate - operating leases		4.88%	4.93%
Maturities of Lease Liabilities [Abstract]
2022		$ 2,775
2023		3,635
2024		2,460
2025		2,145
2026		2,085
Years thereafter		5,343
Total lease payments		18,443
Less: Imputed interest		2,784
Total lease liabilities		15,659		$ 16,312
Cost of Sales [Member]
Components of Lease Expense [Abstract]
Operating lease cost		227	$ 225
Selling, General and Administrative [Member]
Components of Lease Expense [Abstract]
Operating lease cost		$ 690	$ 752
[1]	Variable lease cost includes elements of a contract that do not represent a good or service but for which the lessee is responsible for paying.
[2]	Reported within accrued liabilities on the balance sheet

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Taxes [Abstract]
Effective income tax rate	23.70%	18.70%
Income tax deduction related to exercise of stock options	$ 0.4	$ 3.3

Share Incentive Plans, Equity I

Share Incentive Plans, Equity Incentive Plans (Details) - shares	Mar. 31, 2022	Mar. 22, 2021	Apr. 28, 2016
RSUs [Member]
Share Incentive Plans [Abstract]
Number of awards granted, net of forfeitures (in shares)	87,367
2021 Plan [Member]
Share Incentive Plans [Abstract]
Number of shares authorized for issuance (in shares)		1,290,000
Number of shares available for grant (in shares)	1,189,227
2021 Plan [Member] | RSUs [Member]
Share Incentive Plans [Abstract]
Number of awards granted, net of forfeitures (in shares)	87,367
2021 Plan [Member] | Stock Options [Member]
Share Incentive Plans [Abstract]
Number of awards granted, net of forfeitures (in shares)	95,229
2021 Plan [Member] | Performance-Based Restricted Stock Units [Member]
Share Incentive Plans [Abstract]
Number of awards granted, net of forfeitures (in shares)	18,229
2015 Plan [Member]
Share Incentive Plans [Abstract]
Number of shares authorized for issuance (in shares)		100,052	1,400,000
Number of shares available for grant (in shares)	0
2006 Plan [Member]
Share Incentive Plans [Abstract]
Number of shares available for grant (in shares)	0

Share Incentive Plans, Stock Op

Share Incentive Plans, Stock Option Activity (Details) - 2006, 2015 and 2021 Plans [Member] - Stock Options [Member] - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Stock Option Shares [Roll Forward]
Outstanding, beginning balance (in shares)	619,835	711,060	711,060
Granted (in shares)	100,000		119,500
Exercised (in shares)	(25,166)		(202,768)
Forfeited (in shares)	(7,217)		(7,957)
Outstanding, ending balance (in shares)	687,452		619,835
Weighted Average Exercise Price [Abstract]
Outstanding, beginning balance (in dollars per share)	$ 28.51	$ 19.58	$ 19.58
Granted (in dollars per share)	30.46		50.93
Exercised (in dollars per share)	16.14		10.22
Forfeited (in dollars per share)	29.53		33.22
Outstanding, ending balance (in dollars per share)	29.23		28.51
Weighted Average Grant Date Fair Value [Abstract]
Outstanding, beginning balance (in dollars per share)	8.70	$ 6.42	6.42
Granted (in dollars per share)	10.23		13.58
Exercised (in dollars per share)	4.89		6.35
Forfeited (in dollars per share)	8.13		9.63
Outstanding, ending balance (in dollars per share)	$ 9.07		$ 8.70
Intrinsic value of options exercised	$ 0.4	$ 3.3

Share Incentive Plans, Assumpti

Share Incentive Plans, Assumptions for Options Granted Under 2006 Plan (Details) - 2006 Plan [Member] - Stock Options [Member] - Exercise Price $3.83 [Member]	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Share Incentive Plans [Abstract]
Number of options (in shares) | shares	86,377
Exercise price (in dollars per share)	$ 3.83
Number of options exercisable (in shares) | shares	86,377
Remaining lives	2 years 2 months 8 days
Expected life	10 years
Exercise price (in dollars per share)	$ 3.83
Risk free interest rate	3.57%
Expected volatility	40.00%
Dividend yield	0.00%
Fair value at grant date (in dollars per share)	$ 2.17

Share Incentive Plans, Assump_2

Share Incentive Plans, Assumptions for Options Granted Under 2015 Plan (Details) - 2015 Plan [Member] - Stock Options [Member] - $ / shares	May 03, 2021	Feb. 18, 2021	Mar. 18, 2020	Oct. 24, 2019	Mar. 20, 2019	Mar. 07, 2018	May 17, 2017	Feb. 10, 2017	Mar. 31, 2022
February 10, 2017 [Member]
Share Incentive Plans [Abstract]
Number of options granted (in shares)								40,000
Options outstanding (in shares)									20,000
Number exercisable (in shares)									20,000
Exercise price (in dollars per share)									$ 13
Remaining lives									4 years 10 months 13 days
Risk free interest rate									1.89%
Expected volatility									27.44%
Expected life									6 years
Dividend yield									0.00%
Fair value at grant date (in dollars per share)									$ 3.98
May 17, 2017 [Member]
Share Incentive Plans [Abstract]
Number of options granted (in shares)							93,819
Options outstanding (in shares)									46,483
Number exercisable (in shares)									46,483
Exercise price (in dollars per share)									$ 15.41
Remaining lives									5 years 1 month 17 days
Risk free interest rate									1.76%
Expected volatility									26.92%
Expected life									6 years
Dividend yield									0.00%
Fair value at grant date (in dollars per share)									$ 4.60
March 7, 2018 [Member]
Share Incentive Plans [Abstract]
Number of options granted (in shares)						98,100
Options outstanding (in shares)									58,667
Number exercisable (in shares)									58,667
Exercise price (in dollars per share)									$ 21.21
Remaining lives									5 years 11 months 8 days
Risk free interest rate									2.65%
Expected volatility									28.76%
Expected life									6 years
Dividend yield									0.83%
Fair value at grant date (in dollars per share)									$ 6.37
March 20, 2019 [Member]
Share Incentive Plans [Abstract]
Number of options granted (in shares)					155,780
Options outstanding (in shares)									142,284
Number exercisable (in shares)									142,284
Exercise price (in dollars per share)									$ 47.58
Remaining lives									6 years 11 months 23 days
Risk free interest rate									2.34%
Expected volatility									30.95%
Expected life									6 years
Dividend yield									0.42%
Fair value at grant date (in dollars per share)									$ 15.63
October 24, 2019 [Member]
Share Incentive Plans [Abstract]
Number of options granted (in shares)				25,000
Options outstanding (in shares)									25,000
Number exercisable (in shares)									25,000
Exercise price (in dollars per share)									$ 20.89
Remaining lives									7 years 6 months 25 days
Risk free interest rate									1.58%
Expected volatility									31.93%
Expected life									6 years
Dividend yield									0.95%
Fair value at grant date (in dollars per share)									$ 6.27
March 18, 2020 [Member]
Share Incentive Plans [Abstract]
Number of options granted (in shares)			155,000
Options outstanding (in shares)									94,612
Number exercisable (in shares)									62,148
Exercise price (in dollars per share)									$ 14.85
Remaining lives									7 years 11 months 19 days
Risk free interest rate									0.79%
Expected volatility									35.72%
Expected life									6 years
Dividend yield									1.49%
Fair value at grant date (in dollars per share)									$ 4.41
February 18, 2021 [Member]
Share Incentive Plans [Abstract]
Number of options granted (in shares)		100,000
Options outstanding (in shares)									94,529
Number exercisable (in shares)									39,386
Exercise price (in dollars per share)									$ 51.75
Remaining lives									8 years 10 months 20 days
Risk free interest rate									0.56%
Expected volatility									28.69%
Expected life									6 years
Dividend yield									0.55%
Fair value at grant date (in dollars per share)									$ 13.77
May 3, 2021 [Member]
Share Incentive Plans [Abstract]
Number of options granted (in shares)	12,000
Options outstanding (in shares)									12,000
Number exercisable (in shares)									4,080
Exercise price (in dollars per share)									$ 47.76
Remaining lives									9 years 1 month 6 days
Risk free interest rate									0.84%
Expected volatility									29.03%
Expected life									6 years
Dividend yield									0.59%
Fair value at grant date (in dollars per share)									$ 13.06

Share Incentive Plans, Assump_3

Share Incentive Plans, Assumptions for Options Granted Under 2021 Plan (Details) - 2021 Plan [Member] - Stock Options [Member] - $ / shares	Mar. 14, 2022	May 17, 2021	Mar. 31, 2022
May 17, 2021 [Member]
Share Incentive Plans [Abstract]
Number of options granted (in shares)		7,500
Options outstanding (in shares)			7,500
Number exercisable (in shares)			2,550
Exercise price (in dollars per share)			$ 45.05
Remaining lives			9 years 1 month 17 days
Risk free interest rate			0.84%
Expected volatility			31.50%
Expected life			6 years
Dividend yield			0.63%
Fair value at grant date (in dollars per share)			$ 13.23
March 14, 2022 [Member]
Share Incentive Plans [Abstract]
Number of options granted (in shares)	100,000
Options outstanding (in shares)			100,000
Number exercisable (in shares)			0
Exercise price (in dollars per share)			$ 30.46
Remaining lives			9 years 11 months 15 days
Risk free interest rate			2.10%
Expected volatility			35.33%
Expected life			6 years
Dividend yield			1.01%
Fair value at grant date (in dollars per share)			$ 10.23

Share Incentive Plans, Compensa

Share Incentive Plans, Compensation Expense Related to Options (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Compensation Expense [Abstract]
Compensation expense related to options	$ 0.2	$ 0.3
Unrecognized compensation expense related to options	$ 1.5
Period over which unrecognized compensation expense will be expensed	2 years 4 months 17 days

Share Incentive Plans, Performa

Share Incentive Plans, Performance-Based Restricted Stock Units (Details) - Performance-Based Restricted Stock Units [Member] - USD ($) $ / shares in Units, $ in Millions	Mar. 14, 2022	Feb. 18, 2021	Dec. 28, 2020	Mar. 18, 2020	Jul. 19, 2019	Mar. 20, 2019	Mar. 07, 2018	Mar. 31, 2022	Mar. 31, 2021
Share Incentive Plans [Abstract]
Period between performance period and measurement date								65 days
PRSUs outstanding at March 31, 2022 (in shares)								477,547
Compensation expense								$ 0.8	$ 1.2
Unrecognized compensation expense								$ 6.2
Employees [Member]
Share Incentive Plans [Abstract]
Performance period								5 years
March 7, 2018 [Member] | Employees [Member]
Share Incentive Plans [Abstract]
Number of PRSUs granted (in shares)							96,000
PRSUs outstanding at March 31, 2022 (in shares)								89,600
Fair value as of grant date (in dollars per share)							$ 21.21
Remaining lives								9 months
March 20, 2019 [Member] | Employees [Member]
Share Incentive Plans [Abstract]
Number of PRSUs granted (in shares)						92,500
PRSUs outstanding at March 31, 2022 (in shares)								77,380
Fair value as of grant date (in dollars per share)						$ 47.58
Remaining lives								1 year 9 months
July 19, 2019 [Member] | Employees [Member]
Share Incentive Plans [Abstract]
Number of PRSUs granted (in shares)					88,582
PRSUs outstanding at March 31, 2022 (in shares)								21,342
Fair value as of grant date (in dollars per share)					$ 52.15
Remaining lives								9 months
March 18, 2020 [Member] | Employees [Member]
Share Incentive Plans [Abstract]
Number of PRSUs granted (in shares)				94,000
PRSUs outstanding at March 31, 2022 (in shares)								86,610
Fair value as of grant date (in dollars per share)				$ 14.85
Remaining lives								2 years 9 months
December 28, 2020 [Member] | Employees [Member]
Share Incentive Plans [Abstract]
Number of PRSUs granted (in shares)			88,169
PRSUs outstanding at March 31, 2022 (in shares)								58,779
Fair value as of grant date (in dollars per share)			$ 46.42
Remaining lives								1 year 9 months
February 18, 2021 [Member] | Employees [Member]
Share Incentive Plans [Abstract]
Number of PRSUs granted (in shares)		100,000
PRSUs outstanding at March 31, 2022 (in shares)								93,840
Fair value as of grant date (in dollars per share)		$ 51.75
Remaining lives								3 years 9 months
March 14, 2022 [Member] | Employees [Member]
Share Incentive Plans [Abstract]
Number of PRSUs granted (in shares)	49,996
PRSUs outstanding at March 31, 2022 (in shares)								49,996
Fair value as of grant date (in dollars per share)	$ 30.46
Remaining lives								4 years 9 months

Share Incentive Plans, Restrict

Share Incentive Plans, Restricted Stock Units (Details) - USD ($) $ / shares in Units, $ in Millions	Mar. 14, 2022	Jul. 23, 2021	May 04, 2021	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Period over which unrecognized compensation expense will be expensed				2 years 4 months 17 days
RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Number of awards granted (in shares)				87,367
Compensation expense				$ 0.2
Unrecognized compensation expense				$ 2.4
Period over which unrecognized compensation expense will be expensed				3 years 11 months 15 days
RSUs [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Vesting period				1 year
RSUs [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Vesting period				5 years
RSUs [Member] | May 4, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Number of RSUs granted (in shares)			7,478
RSUs outstanding at March 31, 2022 (in shares)				7,478
Fair value as of grant date (in dollars per share)			$ 47.86
Remaining lives				1 month 2 days
RSUs [Member] | July 23, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Number of RSUs granted (in shares)		1,159
RSUs outstanding at March 31, 2022 (in shares)				1,159
Fair value as of grant date (in dollars per share)		$ 51.81
Remaining lives				3 months 21 days
RSUs [Member] | March 14, 2022 [Member] | Vest in Five Years [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Number of RSUs granted (in shares)	50,004
RSUs outstanding at March 31, 2022 (in shares)				50,004
Fair value as of grant date (in dollars per share)	$ 30.46
Remaining lives				4 years 9 months
RSUs [Member] | March 14, 2022 [Member] | Vest in Three Years [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Number of RSUs granted (in shares)	28,726
RSUs outstanding at March 31, 2022 (in shares)				28,726
Fair value as of grant date (in dollars per share)	$ 30.46
Remaining lives				2 years 9 months

Contingencies (Details)

Contingencies (Details)	Oct. 09, 2020Count	Mar. 31, 2022Subsidiary
Contingencies [Abstract]
Number of derivative counts filed in complaint | Count	2
Number of franchisor subsidiaries | Subsidiary		2

Income Per Share (Details)

Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator [Abstract]
Net income attributable to Turning Point Brands, Inc.	$ 10,998	$ 11,783
Denominator [Abstract]
Basic weighted average shares (in shares)	18,257,695	19,093,961
Basic EPS (in dollars per share)	$ 0.60	$ 0.62
Numerator [Abstract]
Net income attributable to Turning Point Brands, Inc.	$ 10,998	$ 11,783
Interest expense related to Convertible Senior Notes, net of tax	1,054	1,054
Diluted net income attributable to Turning Point Brands. Inc.	$ 12,052	$ 12,837
Denominator [Abstract]
Basic weighted average shares (in shares)	18,257,695	19,093,961
Convertible Senior Notes (in shares)	3,209,690	3,205,895
Stock options (in shares)	282,125	365,211
Diluted weighted average shares (in shares)	21,749,510	22,665,067
Diluted EPS (in dollars per share)	$ 0.55	$ 0.57

Segment Information, Financial

Segment Information, Financial Information of Reportable Segments (Details) $ in Thousands		3 Months Ended
		Mar. 31, 2022USD ($)Segment	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)
Segment Information [Abstract]
Number of reportable segments | Segment		3
Segment Information [Abstract]
Cost of sales		$ 49,100	$ 54,380
Net sales		100,894	107,641
Gross profit		51,794	53,261
Operating income (loss)		19,229	24,349
Interest expense, net		5,196	4,486
Investment income		(78)	(25)
Loss on extinguishment of debt		0	5,706
Income before income taxes		14,111	14,182
Capital expenditures		2,787	842
Depreciation and amortization		1,334	1,265
Assets		618,703		$ 601,560
NewGen Products [Member]
Segment Information [Abstract]
Net sales		23,519	37,382
Reportable Segments [Member] | Zig-Zag Products [Member]
Segment Information [Abstract]
Net sales		45,672	41,004
Gross profit		26,343	24,896
Operating income (loss)		18,737	19,437
Capital expenditures		2,323	0
Depreciation and amortization		92	114
Assets		227,989		227,554
Reportable Segments [Member] | Stoker's Products [Member]
Segment Information [Abstract]
Net sales		31,703	29,255
Gross profit		17,686	15,892
Operating income (loss)		13,506	12,255
Capital expenditures		464	840
Depreciation and amortization		767	635
Assets		172,400		142,334
Reportable Segments [Member] | NewGen Products [Member]
Segment Information [Abstract]
Net sales		23,519	37,382
Gross profit		7,765	12,473
Operating income (loss)		678	2,006
Capital expenditures		0	2
Depreciation and amortization		475	516
Assets		61,529		72,746
Reportable Segments [Member] | NewGen Products [Member] | Plan [Member]
Segment Information [Abstract]
Cost of sales			(900)
Corporate Unallocated [Member]
Segment Information [Abstract]
Operating income (loss)	[1],[2]	(13,692)	(9,349)
Operating costs related to PMTA		1,100	300
Assets	[3]	$ 156,785		$ 158,926
Corporate Unallocated [Member] | Plan [Member]
Segment Information [Abstract]
Cost of sales			$ 900
[1]	Includes corporate costs that are not allocated to any of the three reportable segments.
[2]	Includes costs related to PMTA of $1.1 million in 2022 and $0.3 million in 2021.
[3]	Includes assets not assigned to the three reportable segments. All goodwill has been allocated to the reportable segments.

Segment Information, Revenue Di

Segment Information, Revenue Disaggregation - Sales Channel (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net Sales by Sales Channel [Abstract]
Net sales	$ 100,894	$ 107,641
NewGen Products [Member]
Net Sales by Sales Channel [Abstract]
Net sales	23,519	37,382
NewGen Products [Member] | Business to Business [Member]
Net Sales by Sales Channel [Abstract]
Net sales	19,124	27,257
NewGen Products [Member] | Business to Consumer - Online [Member]
Net Sales by Sales Channel [Abstract]
Net sales	4,233	10,033
NewGen Products [Member] | Other [Member]
Net Sales by Sales Channel [Abstract]
Net sales	$ 162	$ 92

Segment Information, Net Sales

Segment Information, Net Sales - Domestic and Foreign (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Information [Abstract]
Net sales	$ 100,894	$ 107,641
Reportable Geographical Component [Member] | Domestic [Member]
Segment Information [Abstract]
Net sales	93,766	100,127
Reportable Geographical Component [Member] | Foreign [Member]
Segment Information [Abstract]
Net sales	$ 7,128	$ 7,514

Dividends and Share Repurchase

Dividends and Share Repurchase (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 08, 2022	Mar. 31, 2022	Mar. 31, 2021	Feb. 24, 2022	Oct. 25, 2021	Feb. 25, 2020
Share Repurchase [Abstract]
Share repurchase program authorized amount				$ 24,600	$ 30,700	$ 50,000
Total number of shares repurchased (in shares)		310,224
Cost of shares repurchased		$ 10,622	$ 5,733
Average price per share (in dollars per share)		$ 34.24
Remaining share repurchase program authorized amount		$ 45,800
Dividend Declared Q1-2022 [Member]
Dividends [Abstract]
Dividend payable, date to be paid		Apr. 8, 2022
Dividend payable, date of record		Mar. 18, 2022
Dividend Declared Q1-2022 [Member] | Subsequent Event [Member]
Dividends [Abstract]
Cash dividend paid (in dollars per share)	$ 0.06